{"id":"alendronic-acid","rwe":[],"_fda":{"id":"10aeb309-f6e1-49c6-ac6f-ad743db28527","set_id":"10307e7e-9a84-4aa1-8c5c-4b209cffe4d1","openfda":{"nui":["M0022797","N0000175952"],"unii":["1C6V77QF41","2UY4M2U3RA"],"route":["ORAL"],"rxcui":["904462","904465","904492","904495"],"spl_id":["10aeb309-f6e1-49c6-ac6f-ad743db28527"],"brand_name":["FOSAMAX PLUS D"],"spl_set_id":["10307e7e-9a84-4aa1-8c5c-4b209cffe4d1"],"package_ndc":["78206-137-01","78206-136-01"],"product_ndc":["78206-136","78206-137"],"generic_name":["ALENDRONATE SODIUM AND CHOLECALCIFEROL"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Vitamin D [CS]"],"substance_name":["ALENDRONATE SODIUM","CHOLECALCIFEROL"],"pharm_class_epc":["Vitamin D [EPC]"],"manufacturer_name":["Organon LLC"],"application_number":["NDA021762"],"is_original_packager":[true]},"version":"10","pregnancy":["8.1 Pregnancy Risk Summary Available data on the use of FOSAMAX plus vitamin D use in pregnant women are insufficient to inform a drug-associated risk of adverse maternal or fetal outcomes. Discontinue FOSAMAX PLUS D when pregnancy is recognized. Alendronate Sodium In animal reproduction studies, daily oral administration of alendronate to rats from before mating through the end of gestation or lactation showed decreased postimplantation survival and decreased pup body weight gain starting at doses equivalent to less than half of the highest recommended 40 mg clinical daily dose (based on body surface area, mg/m 2 ). Oral administration of alendronate to rats during organogenesis resulted in reduced fetal ossification starting at doses 3 times the 40 mg clinical daily dose. No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at doses equivalent to approximately 10 times the 40 mg clinical daily dose. Delayed or failed delivery of offspring, protracted parturition, and late pregnancy maternal and fetal deaths due to maternal hypocalcemia occurred in rats at oral doses as low as one tenth the 40 mg clinical daily dose (see Data ) . Bisphosphonates are incorporated into the bone matrix, from which they are gradually released over a period of years. The amount of bisphosphonate incorporated into adult bone and available for release into the systemic circulation is directly related to the dose and duration of bisphosphonate use. Consequently, based on the mechanism of action of bisphosphonates, there is a potential risk of fetal harm, predominantly skeletal, if a woman becomes pregnant after completing a course of bisphosphonate therapy. The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of administration (intravenous versus oral) on the risk has not been studied. Cholecalciferol No data are available for cholecalciferol (vitamin D 3 ) in animals. However, administration of high doses of vitamin D 2 to pregnant rabbits resulted in abortions and an increased incidence of fetal aortic stenosis. Administration of high doses of vitamin D 2 to pregnant rats resulted in neonatal death, decreased fetal weight, and impaired osteogenesis of long bones postnatally. (See Data .) The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Alendronate Sodium Reproduction studies in rats dosed orally from before mating to the end of gestation or lactation showed decreased postimplantation survival starting at 2 mg/kg/day and decreased body weight gain starting at 1 mg/kg/day, doses equivalent to less than half the 40 mg clinical daily dose based on body surface area, mg/m 2 . Incidence of incomplete fetal ossification in vertebral, skull, and sternebral bones were increased in rats dosed orally during organogenesis starting at 10 mg/kg/day (approximately 3 times the 40 mg clinical daily dose). No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at up to 35 mg/kg/day (equivalent to approximately 10 times the 40 mg clinical daily dose). Both total and ionized calcium decreased in pregnant rats dosed orally with 15 mg/kg/day alendronate (approximately 4 times the 40 mg clinical daily dose) resulting in delays and failures of delivery. Protracted parturition due to maternal hypocalcemia was observed when rats were treated from before mating through gestation starting at 0.5 mg/kg/day (approximately one tenth the 40 mg clinical daily dose). Maternotoxicity (late pregnancy deaths) also occurred in female rats treated orally with 15 mg/kg/day (approximately 4 times the 40 mg clinical daily dose) for varying gestational time periods. These maternal deaths were lessened but not eliminated by cessation of treatment. Calcium supplementation in the drinking water or by subcutaneous minipump to rats dosed orally with 15 mg/kg/day alendronate could not ameliorate the hypocalcemia or prevent the dystocia-related maternal and neonatal deaths. However, intravenous calcium supplementation prevented maternal, but not neonatal deaths. Cholecalciferol Administration of high doses (greater than or equal to 10,000 international units/every other day during pregnancy) of ergocalciferol (vitamin D 2 ) to pregnant rabbits resulted in abortions and an increased incidence of fetal aortic stenosis. Administration of vitamin D 2 (40,000 international units/day) to pregnant rats from gestation day 10 to 21 (organogenesis) resulted in neonatal death, decreased fetal weight, and impaired osteogenesis of long bones postnatally."],"overdosage":["10 OVERDOSAGE Alendronate Sodium Significant lethality after single oral doses with alendronate was seen in female rats and mice at 552 mg/kg (3256 mg/m 2 ) and 966 mg/kg (2898 mg/m 2 ), respectively. In males, these values were slightly higher, 626 and 1280 mg/kg, respectively. There was no lethality in dogs at oral doses up to 200 mg/kg (4000 mg/m 2 ). No specific information is available on the treatment of overdosage with alendronate. Hypocalcemia, hypophosphatemia, and upper gastrointestinal adverse events, such as upset stomach, heartburn, esophagitis, gastritis, or ulcer, may result from oral overdosage. Milk or antacids should be given to bind alendronate. Due to the risk of esophageal irritation, vomiting should not be induced and the patient should remain fully upright. Dialysis would not be beneficial. Cholecalciferol Significant lethality occurred in mice treated with a single high oral dose of calcitriol (4 mg/kg), the hormonal metabolite of cholecalciferol. There is limited information regarding doses of cholecalciferol associated with acute toxicity, although intermittent (yearly or twice yearly) single doses of ergocalciferol (vitamin D 2 ) as high as 600,000 international units have been given without reports of toxicity. Signs and symptoms of vitamin D toxicity include hypercalcemia, hypercalciuria, anorexia, nausea, vomiting, polyuria, polydipsia, weakness, and lethargy. Serum and urine calcium levels should be monitored in patients with suspected vitamin D toxicity. Standard therapy includes restriction of dietary calcium, hydration, and systemic glucocorticoids in patients with severe hypercalcemia. Dialysis to remove vitamin D would not be beneficial."],"description":["11 DESCRIPTION FOSAMAX PLUS D contains alendronate sodium, a bisphosphonate, and cholecalciferol (vitamin D 3 ). Alendronate sodium is a bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Bisphosphonates are synthetic analogs of pyrophosphate that bind to the hydroxyapatite found in bone. Alendronate sodium is chemically described as (4-amino-1-hydroxybutylidene) bisphosphonic acid monosodium salt trihydrate. The empirical formula of alendronate sodium is C 4 H 12 NNaO 7 P 2 •3H 2 O and its formula weight is 325.12. The structural formula is: Alendronate sodium is a white, crystalline, nonhygroscopic powder. It is soluble in water, very slightly soluble in alcohol, and practically insoluble in chloroform. Cholecalciferol (vitamin D 3 ) is a secosterol that is the natural precursor of the calcium-regulating hormone calcitriol (1,25 dihydroxyvitamin D 3 ). The chemical name of cholecalciferol is (3β,5 Z ,7 E )-9,10-secocholesta-5,7,10(19)-trien-3-ol. The empirical formula of cholecalciferol is C 27 H 44 O and its molecular weight is 384.6. The structural formula is: Cholecalciferol is a white, crystalline, odorless powder. Cholecalciferol is practically insoluble in water, freely soluble in usual organic solvents, and slightly soluble in vegetable oils. FOSAMAX PLUS D for oral administration contains 91.37 mg of alendronate monosodium salt trihydrate, the molar equivalent of 70 mg of free acid, and 70 or 140 mcg of cholecalciferol, equivalent to 2800 or 5600 international units vitamin D, respectively. Each tablet contains the following inactive ingredients: microcrystalline cellulose, lactose anhydrous, medium chain triglycerides, gelatin, croscarmellose sodium, sucrose, colloidal silicon dioxide, magnesium stearate, butylated hydroxytoluene, modified food starch, and sodium aluminum silicate. image of alendronate sodium structural formula image of cholecalciferol structural formula"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING FOSAMAX PLUS D 70 mg/2800 international units are white to off-white, modified capsule-shaped tablets with code 710 on one side and an outline of a bone image on the other. They are supplied as follows: NDC 78206-137-01 unit of use blister packages of 4. FOSAMAX PLUS D 70 mg/5600 international units are white to off-white, modified rectangle-shaped tablets with code 270 on one side and an outline of a bone image on the other. They are supplied as follows: NDC 78206-136-01 unit of use blister packages of 4 Storage Store at 68°F to 77°F (20°C to 25°C), excursions between 59°F to 86°F (15°C to 30°C). are allowed. [See USP Controlled Room Temperature.] Protect from moisture and light. Store tablets in the original blister package until use."],"spl_medguide":["MEDICATION GUIDE FOSAMAX ® PLUS D (FOSS-ah-max PLUS D) (alendronate sodium/cholecalciferol) Tablets Read the Medication Guide that comes with FOSAMAX ® PLUS D before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or treatment. Talk to your doctor if you have any questions about FOSAMAX PLUS D. What is the most important information I should know about FOSAMAX PLUS D? FOSAMAX PLUS D can cause serious side effects including: Esophagus problems Low calcium levels in your blood (hypocalcemia) Bone, joint, or muscle pain Severe jaw bone problems (osteonecrosis) Unusual breaks in thigh and other bones Esophagus problems. Some people who take FOSAMAX PLUS D may develop problems in the esophagus (the tube that connects the mouth and the stomach). These problems include irritation, inflammation, or ulcers of the esophagus which may sometimes bleed. It is important that you take FOSAMAX PLUS D exactly as prescribed to help lower your chance of getting esophagus problems. (See the section \"How should I take FOSAMAX PLUS D tablet?\") Stop taking FOSAMAX PLUS D and call your doctor right away if you get chest pain, new or worsening heartburn, or have trouble or pain when you swallow. Low calcium levels in your blood (hypocalcemia). FOSAMAX PLUS D may lower the calcium levels in your blood. If you have low blood calcium before you start taking FOSAMAX PLUS D, it may get worse during treatment. Your low blood calcium must be treated before you take FOSAMAX PLUS D. Most people with low blood calcium levels do not have symptoms, but some people may have symptoms. Call your doctor right away if you have symptoms of low blood calcium such as: Spasms, twitches, or cramps in your muscles Numbness or tingling in your fingers, toes, or around your mouth Your doctor may prescribe calcium and vitamin D to help prevent low calcium levels in your blood, while you take FOSAMAX PLUS D. Take calcium and vitamin D as your doctor tells you to. Bone, joint, or muscle pain. Some people who take FOSAMAX PLUS D develop severe bone, joint, or muscle pain. Severe jaw bone problems (osteonecrosis). Severe jaw bone problems may happen when you take FOSAMAX PLUS D. Your doctor should examine your mouth before you start FOSAMAX PLUS D. Your doctor may tell you to see your dentist before you start FOSAMAX PLUS D. It is important for you to practice good mouth care during treatment with FOSAMAX PLUS D. Unusual breaks in thigh and other bones. Some people have had unusual bone breaks, including thigh bone when taking FOSAMAX PLUS D. A break in the thigh bone can feel like a new pain in your hip, groin, or thigh. People taking FOSAMAX PLUS D can also have breaks in other bones. Call your doctor right away if you have any of these side effects. What is FOSAMAX PLUS D? FOSAMAX PLUS D is a prescription medicine used to: Treat osteoporosis in women after menopause. FOSAMAX PLUS D helps increase bone mass and reduces the chance of having a hip or spinal fracture (break). Increase bone mass in men with osteoporosis. FOSAMAX PLUS D should not be used to treat vitamin D deficiency. It is not known how long FOSAMAX PLUS D works for the treatment of osteoporosis. You should see your doctor regularly to determine if FOSAMAX PLUS D is still right for you. FOSAMAX PLUS D is not for use in children. Who should not take FOSAMAX PLUS D? Do not take FOSAMAX PLUS D if you: Have certain problems with your esophagus, the tube that connects your mouth with your stomach Cannot stand or sit upright for at least 30 minutes Have low levels of calcium in your blood Are allergic to FOSAMAX PLUS D or any of its ingredients. A list of ingredients is at the end of this leaflet. What should I tell my doctor before taking FOSAMAX PLUS D? Before you start FOSAMAX PLUS D, be sure to talk to your doctor if you: Have problems with swallowing Have stomach or digestive problems Have low blood calcium Plan to have dental surgery or teeth removed Have kidney problems Have sarcoidosis, leukemia, lymphoma. These conditions may cause changes in vitamin D. Have been told you have trouble absorbing minerals in your stomach or intestines (malabsorption syndrome) Are pregnant, trying to become pregnant or suspect that you are pregnant. If you become pregnant while taking FOSAMAX PLUS D, stop taking it and contact your doctor. It is not known if FOSAMAX PLUS D can harm your unborn baby. Are breast-feeding or plan to breast-feed. It is not known if FOSAMAX PLUS D passes into your milk and may harm your baby. Especially tell your doctor if you take: antacids aspirin Nonsteroidal Anti-Inflammatory (NSAID) medicines Tell your doctor about all the medicines you take , including prescription and non-prescription medicines, vitamins, and herbal supplements. Certain medicines may affect how FOSAMAX PLUS D works. Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist each time you get a new medicine. How should I take FOSAMAX PLUS D tablet? Take FOSAMAX PLUS D exactly as your doctor tells you. FOSAMAX PLUS D works only if taken on an empty stomach. Take 1 dose of FOSAMAX PLUS D 1 time a week, after you get up for the day and before taking your first food, drink, or other medicine. Take FOSAMAX PLUS D while you are sitting or standing. Take your FOSAMAX PLUS D tablet with a full glass (6-8 oz) of plain water. Do not chew or suck on a tablet of FOSAMAX PLUS D. Do not take FOSAMAX PLUS D with mineral water, coffee, tea, soda, or juice. Do not take FOSAMAX PLUS D at bedtime. After swallowing FOSAMAX PLUS D, wait at least 30 minutes: Before you lie down. You may sit, stand or walk, and do normal activities like reading. Before you take your first food or drink except for plain water. Before you take other medicines, including antacids, calcium, and other supplements and vitamins. Do not lie down for at least 30 minutes after you take FOSAMAX PLUS D and after you eat your first food of the day. If you miss a dose of FOSAMAX PLUS D, do not take it later in the day. Take your missed dose on the next morning after you remember and then return to your normal schedule. Do not take 2 doses on the same day. If you take too much FOSAMAX PLUS D, call your doctor. Do not try to vomit. Do not lie down. What are the possible side effects of FOSAMAX PLUS D? FOSAMAX PLUS D may cause serious side effects. See \"What is the most important information I should know about FOSAMAX PLUS D?\" The most common side effects of FOSAMAX PLUS D are: Stomach area (abdominal) pain Heartburn Constipation Diarrhea Upset stomach Pain in your bones, joints, or muscles Nausea You may get allergic reactions, such as hives or swelling of your face, lips, tongue, or throat. Worsening of asthma has been reported. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of FOSAMAX PLUS D. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How do I store FOSAMAX PLUS D? Store FOSAMAX PLUS D at room temperature, 68°F to 77°F (20°C to 25°C). Keep FOSAMAX PLUS D away from light. Keep FOSAMAX PLUS D package and tablets dry. Store FOSAMAX PLUS D in the original package. Keep FOSAMAX PLUS D and all medicines out of the reach of children. General information about the safe and effective use of FOSAMAX PLUS D. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use FOSAMAX PLUS D for a condition for which it was not prescribed. Do not give FOSAMAX PLUS D to other people, even if they have the same symptoms you have. It may harm them. This Medication Guide summarizes the most important information about FOSAMAX PLUS D. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about FOSAMAX PLUS D that is written for health professionals. What are the ingredients in FOSAMAX PLUS D? Active ingredients: alendronate sodium and cholecalciferol (vitamin D 3 ). Inactive ingredients: cellulose, lactose, medium chain triglycerides, gelatin, croscarmellose sodium, sucrose, colloidal silicon dioxide, magnesium stearate, butylated hydroxytoluene, modified food starch, and sodium aluminum silicate."],"geriatric_use":["8.5 Geriatric Use Of the patients receiving FOSAMAX in the Fracture Intervention Trial (FIT), 71% (n=2302) were greater than or equal to 65 years of age and 17% (n=550) were greater than or equal to 75 years of age. Of the patients receiving FOSAMAX in the United States and Multinational osteoporosis treatment studies in women, and osteoporosis studies in men [see Clinical Studies ( 14.1 , 14.2 )] , 45% and 54%, respectively, were 65 years of age or over. No overall differences in efficacy or safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Dietary requirements of vitamin D 3 are increased in the elderly."],"pediatric_use":["8.4 Pediatric Use FOSAMAX PLUS D is not indicated for use in pediatric patients. The safety and efficacy of alendronate were examined in a randomized, double-blind, placebo-controlled two-year study of 139 pediatric patients, aged 4-18 years, with severe osteogenesis imperfecta (OI). One-hundred-and-nine patients were randomized to 5 mg alendronate daily (weight less than 40 kg) or 10 mg alendronate daily (weight greater than or equal to 40 kg) and 30 patients to placebo. The mean baseline lumbar spine BMD Z-score of the patients was -4.5. The mean change in lumbar spine BMD Z-score from baseline to Month 24 was 1.3 in the alendronate-treated patients and 0.1 in the placebo-treated patients. Treatment with alendronate did not reduce the risk of fracture. Sixteen percent of the alendronate patients who sustained a radiologically-confirmed fracture by Month 12 of the study had delayed fracture healing (callus remodeling) or fracture non-union when assessed radiographically at Month 24 compared with 9% of the placebo-treated patients. In alendronate-treated patients, bone histomorphometry data obtained at Month 24 demonstrated decreased bone turnover and delayed mineralization time; however, there were no mineralization defects. There were no statistically significant differences between the alendronate and placebo groups in reduction of bone pain. The oral bioavailability of alendronate in children was similar to that observed in adults."],"effective_time":"20260203","clinical_studies":["14 CLINICAL STUDIES 14.1 Treatment of Osteoporosis in Postmenopausal Women FOSAMAX Daily The efficacy of FOSAMAX 10 mg daily was assessed in four clinical trials. Study 1, a three-year, multicenter, double-blind, placebo-controlled, US clinical study enrolled 478 patients with a BMD T-score at or below minus 2.5 with or without a prior vertebral fracture; Study 2, a three-year, multicenter, double-blind, placebo-controlled, Multinational clinical study enrolled 516 patients with a BMD T-score at or below minus 2.5 with or without a prior vertebral fracture; Study 3, the Three-Year Study of the Fracture Intervention Trial (FIT), a study which enrolled 2027 postmenopausal patients with at least one baseline vertebral fracture; and Study 4, the Four-Year Study of FIT, a study which enrolled 4432 postmenopausal patients with low bone mass but without a baseline vertebral fracture. Effect on Fracture Incidence To assess the effects of FOSAMAX on the incidence of vertebral fractures (detected by digitized radiography; approximately one third of these were clinically symptomatic), the U.S. and Multinational studies were combined in an analysis that compared placebo to the pooled dosage groups of FOSAMAX (5 or 10 mg for three years or 20 mg for two years followed by 5 mg for one year). There was a statistically significant reduction in the proportion of patients treated with FOSAMAX experiencing one or more new vertebral fractures relative to those treated with placebo (3.2% vs. 6.2%; a 48% relative risk reduction). A reduction in the total number of new vertebral fractures (4.2 vs. 11.3 per 100 patients) was also observed. In the pooled analysis, patients who received FOSAMAX had a loss in stature that was statistically significantly less than was observed in those who received placebo (-3.0 mm vs. -4.6 mm). The Fracture Intervention Trial (FIT) consisted of two studies in postmenopausal women: the Three-Year Study of patients who had at least one baseline radiographic vertebral fracture and the Four-Year Study of patients with low bone mass but without a baseline vertebral fracture. In both studies of FIT, 96% of randomized patients completed the studies (i.e., had a closeout visit at the scheduled end of the study); approximately 80% of patients were still taking study medication upon completion. Fracture Intervention Trial: Three-Year Study (patients with at least one baseline radiographic vertebral fracture) This randomized, double-blind, placebo-controlled, 2027-patient study (FOSAMAX, n=1022; placebo, n=1005) demonstrated that treatment with FOSAMAX resulted in statistically significant reductions in fracture incidence at three years as shown in Table 6. Table 6: Effect of FOSAMAX on Fracture Incidence in the Three-Year Study of FIT (patients with vertebral fracture at baseline) Percent of Patients FOSAMAX (n=1022) Placebo (n=1005) Absolute Reduction in Fracture Incidence Relative Reduction in Fracture Risk % Patients with: Vertebral fractures (diagnosed by X-ray) Number evaluable for vertebral fractures: FOSAMAX, n=984; placebo, n=966 ≥1 new vertebral fracture 7.9 15.0 7.1 47 p<0.001 ≥2 new vertebral fractures 0.5 4.9 4.4 90 Clinical (symptomatic) fractures Any clinical (symptomatic) fracture 13.8 18.1 4.3 26 p=0.007 ≥1 clinical (symptomatic) vertebral fracture 2.3 5.0 2.7 54 p<0.01 Hip fracture 1.1 2.2 1.1 51 p<0.05 Wrist (forearm) fracture 2.2 4.1 1.9 48 Furthermore, in this population of patients with baseline vertebral fracture, treatment with FOSAMAX significantly reduced the incidence of hospitalizations (25.0% vs. 30.7%). In the Three-Year Study of FIT, fractures of the hip occurred in 22 (2.2%) of 1005 patients on placebo and 11 (1.1%) of 1022 patients on FOSAMAX, p=0.047. Figure 1 displays the cumulative incidence of hip fractures in this study. Figure 1: Cumulative Incidence of Hip Fractures in the Three-Year Study of FIT (patients with radiographic vertebral fracture at baseline) Fracture Intervention Trial: Four-Year Study (patients with low bone mass but without a baseline radiographic vertebral fracture) This randomized, double-blind, placebo-controlled, 4432-patient study (FOSAMAX, n=2214; placebo, n=2218) further investigated the reduction in fracture incidence due to FOSAMAX. The intent of the study was to recruit women with osteoporosis, defined as a baseline femoral neck BMD at least two standard deviations below the mean for young adult women. However, due to subsequent revisions to the normative values for femoral neck BMD, 31% of patients were found not to meet this entry criterion and thus this study included both osteoporotic and non-osteoporotic women. The results are shown in Table 7 below for the patients with osteoporosis. Table 7: Effect of FOSAMAX on Fracture Incidence in Osteoporotic Baseline femoral neck BMD at least 2 SD below the mean for young adult women Patients in the Four-Year Study of FIT (patients without vertebral fracture at baseline) Percent of Patients FOSAMAX (n=1545) Placebo (n=1521) Absolute Reduction in Fracture Incidence Relative Reduction in Fracture Risk (%) Patients with: Vertebral fractures (diagnosed by X-ray) Number evaluable for vertebral fractures: FOSAMAX, n=1426; placebo, n=1428 ≥1 new vertebral fracture 2.5 4.8 2.3 48 p<0.001 ≥2 new vertebral fractures 0.1 0.6 0.5 78 p=0.035 Clinical (symptomatic) fractures Any clinical (symptomatic) fracture 12.9 16.2 3.3 22 p=0.01 ≥1 clinical (symptomatic) vertebral fracture 1.0 1.6 0.6 41 (NS) Not significant. This study was not powered to detect differences at these sites. Hip fracture 1.0 1.4 0.4 29 (NS) Wrist (forearm) fracture 3.9 3.8 -0.1 NS Fracture Results Across Studies In the Three-Year Study of FIT, FOSAMAX reduced the percentage of women experiencing at least one new radiographic vertebral fracture from 15.0% to 7.9% (47% relative risk reduction, p<0.001); in the Four-Year Study of FIT, the percentage was reduced from 3.8% to 2.1% (44% relative risk reduction, p=0.001); and in the combined U.S./Multinational studies, from 6.2% to 3.2% (48% relative risk reduction, p=0.034). FOSAMAX reduced the percentage of women experiencing multiple (two or more) new vertebral fractures from 4.2% to 0.6% (87% relative risk reduction, p<0.001) in the combined U.S./Multinational studies and from 4.9% to 0.5% (90% relative risk reduction, p<0.001) in the Three-Year Study of FIT. In the Four-Year Study of FIT, FOSAMAX reduced the percentage of osteoporotic women experiencing multiple vertebral fractures from 0.6% to 0.1% (78% relative risk reduction, p=0.035). Thus, FOSAMAX reduced the incidence of radiographic vertebral fractures in osteoporotic women whether or not they had a previous radiographic vertebral fracture. Effect on Bone Mineral Density The bone mineral density efficacy of FOSAMAX 10 mg once daily in postmenopausal women, 44 to 84 years of age, with osteoporosis (lumbar spine bone mineral density [BMD] of at least 2 standard deviations below the premenopausal mean) was demonstrated in four double-blind, placebo-controlled clinical studies of two or three years' duration. Figure 2 shows the mean increases in BMD of the lumbar spine, femoral neck, and trochanter in patients receiving FOSAMAX 10 mg/day relative to placebo-treated patients at three years for each of these studies. Figure 2: At three years significant increases in BMD, relative both to baseline and placebo, were seen at each measurement site in each study in patients who received FOSAMAX 10 mg/day. Total body BMD also increased significantly in each study, suggesting that the increases in bone mass of the spine and hip did not occur at the expense of other skeletal sites. Increases in BMD were evident as early as three months and continued throughout the three years of treatment. (See figure 3 for lumbar spine results.) In the two-year extension of these studies, treatment of 147 patients with FOSAMAX 10 mg/day resulted in continued increases in BMD at the lumbar spine and trochanter (absolute additional increases between years 3 and 5: lumbar spine, 0.94%; trochanter, 0.88%). BMD at the femoral neck, forearm and total body were maintained. FOSAMAX was similarly effective regardless of age, race, baseline rate of bone turnover, and baseline BMD in the range studied (at least 2 standard deviations below the premenopausal mean). Figure 3: In patients with postmenopausal osteoporosis treated with FOSAMAX 10 mg/day for one or two years, the effects of treatment withdrawal were assessed. Following discontinuation, there were no further increases in bone mass and the rates of bone loss were similar to those of the placebo groups. Bone Histology Bone histology in 270 postmenopausal patients with osteoporosis treated with FOSAMAX at doses ranging from 1 to 20 mg/day for one, two, or three years revealed normal mineralization and structure, as well as the expected decrease in bone turnover relative to placebo. These data, together with the normal bone histology and increased bone strength observed in rats and baboons exposed to long-term alendronate treatment, support the conclusion that bone formed during therapy with FOSAMAX is of normal quality. Effect on Height FOSAMAX, over a three- or four-year period, was associated with statistically significant reductions in loss of height vs. placebo in patients with and without baseline radiographic vertebral fractures. At the end of the FIT studies, the between-treatment group differences were 3.2 mm in the Three-Year Study and 1.3 mm in the Four-Year Study. FOSAMAX Once-Weekly The therapeutic equivalence of once-weekly FOSAMAX 70 mg (n=519) and FOSAMAX 10 mg daily (n=370) was demonstrated in a one-year, double-blind, multicenter study of postmenopausal women with osteoporosis. In the primary analysis of completers, the mean increases from baseline in lumbar spine BMD at one year were 5.1% (4.8, 5.4%; 95% CI) in the 70-mg once-weekly group (n=440) and 5.4% (5.0, 5.8%; 95% CI) in the 10-mg daily group (n=330). The two treatment groups were also similar with regard to BMD increases at other skeletal sites. The results of the intention-to-treat analysis were consistent with the primary analysis of completers. Concomitant Use with Estrogen Hormone Replacement Therapy The effects on BMD of treatment with FOSAMAX 10 mg once daily and conjugated estrogen (0.625 mg/day) either alone or in combination were assessed in a two-year, double-blind, placebo-controlled study of hysterectomized postmenopausal osteoporotic women (n=425). At two years, the increases in lumbar spine BMD from baseline were significantly greater with the combination (8.3%) than with either estrogen or FOSAMAX alone (both 6.0%). The effects on BMD when FOSAMAX was added to stable doses (for at least one year) of HRT (estrogen ± progestin) were assessed in a one-year, double-blind, placebo-controlled study in postmenopausal osteoporotic women (n=428). The addition of FOSAMAX 10 mg once daily to HRT produced, at one year, significantly greater increases in lumbar spine BMD (3.7%) vs. HRT alone (1.1%). In these studies, significant increases or favorable trends in BMD for combined therapy compared with HRT alone were seen at the total hip, femoral neck, and trochanter. No significant effect was seen for total body BMD. Histomorphometric studies of transiliac biopsies in 92 subjects showed normal bone architecture. Compared to placebo there was a 98% suppression of bone turnover (as assessed by mineralizing surface) after 18 months of combined treatment with FOSAMAX and HRT, 94% on FOSAMAX alone, and 78% on HRT alone. The long-term effects of combined FOSAMAX and HRT on fracture occurrence and fracture healing have not been studied. 14.2 Treatment to Increase Bone Mass in Men with Osteoporosis The efficacy of FOSAMAX in men with hypogonadal or idiopathic osteoporosis was demonstrated in two clinical studies. FOSAMAX Daily A two-year, double-blind, placebo-controlled, multicenter study of FOSAMAX 10 mg once daily enrolled a total of 241 men between the ages of 31 and 87 (mean, 63). All patients in the trial had either a BMD T-score less than or equal to -2 at the femoral neck and less than or equal to -1 at the lumbar spine, or a baseline osteoporotic fracture and a BMD T-score less than or equal to -1 at the femoral neck. At two years, the mean increases relative to placebo in BMD in men receiving FOSAMAX 10 mg/day were significant at the following sites: lumbar spine, 5.3%; femoral neck, 2.6%; trochanter, 3.1%; and total body, 1.6%. Treatment with FOSAMAX also reduced height loss (FOSAMAX, -0.6 mm vs. placebo, -2.4 mm). FOSAMAX Once-Weekly A one-year, double-blind, placebo-controlled, multicenter study of once weekly FOSAMAX 70 mg enrolled a total of 167 men between the ages of 38 and 91 (mean, 66). Patients in the study had either a BMD T-score less than or equal to -2 at the femoral neck and less than or equal to -1 at the lumbar spine, or a BMD T-score less than or equal to -2 at the lumbar spine and less than or equal to -1 at the femoral neck, or a baseline osteoporotic fracture and a BMD T-score less than or equal to -1 at the femoral neck. At one year, the mean increases relative to placebo in BMD in men receiving FOSAMAX 70 mg once weekly were significant at the following sites: lumbar spine, 2.8%; femoral neck, 1.9%; trochanter, 2.0%; and total body, 1.2%. These increases in BMD were similar to those seen at one year in the 10 mg once-daily study. In both studies, BMD responses were similar regardless of age (greater than or equal to 65 years vs. less than 65 years), gonadal function (baseline testosterone less than 9 ng/dL vs. greater than or equal to 9 ng/dL), or baseline BMD (femoral neck and lumbar spine T-score less than or equal to -2.5 vs. greater than -2.5). image of Figure 1 image of Figure 2 image of Figure 3"],"pharmacodynamics":["12.2 Pharmacodynamics Alendronate Sodium Alendronate is a bisphosphonate that binds to bone hydroxyapatite and specifically inhibits the activity of osteoclasts, the bone-resorbing cells. Alendronate reduces bone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled during bone turnover. Daily oral doses of alendronate (5, 20, and 40 mg for six weeks) in postmenopausal women produced biochemical changes indicative of dose-dependent inhibition of bone resorption, including decreases in urinary calcium and urinary markers of bone collagen degradation (such as deoxypyridinoline and cross-linked N-telopeptides of type I collagen). These biochemical changes tended to return toward baseline values as early as 3 weeks following the discontinuation of therapy with alendronate and did not differ from placebo after 7 months. Long-term treatment of osteoporosis with FOSAMAX 10 mg/day (for up to five years) reduced urinary excretion of markers of bone resorption, deoxypyridinoline and cross-linked N-telopeptides of type l collagen, by approximately 50% and 70%, respectively, to reach levels similar to those seen in healthy premenopausal women. The decrease in the rate of bone resorption indicated by these markers was evident as early as one month and at three to six months reached a plateau that was maintained for the entire duration of treatment with FOSAMAX. In osteoporosis treatment studies FOSAMAX 10 mg/day decreased the markers of bone formation, osteocalcin and bone specific alkaline phosphatase by approximately 50%, and total serum alkaline phosphatase by approximately 25 to 30% to reach a plateau after 6 to 12 months. Similar reductions in the rate of bone turnover were observed in postmenopausal women during one-year studies with once weekly FOSAMAX 70 mg for the treatment of osteoporosis. These data indicate that the rate of bone turnover reached a new steady-state, despite the progressive increase in the total amount of alendronate deposited within bone. As a result of inhibition of bone resorption, asymptomatic reductions in serum calcium and phosphate concentrations were also observed following treatment with FOSAMAX. In the long-term studies, reductions from baseline in serum calcium (approximately 2%) and phosphate (approximately 4 to 6%) were evident the first month after the initiation of FOSAMAX 10 mg. No further decreases in serum calcium were observed for the five-year duration of treatment; however, serum phosphate returned toward prestudy levels during years three through five. In one-year studies with once weekly FOSAMAX 70 mg, similar reductions were observed at 6 and 12 months. The reduction in serum phosphate may reflect not only the positive bone mineral balance due to FOSAMAX but also a decrease in renal phosphate reabsorption. Osteoporosis in Men Treatment of men with osteoporosis with FOSAMAX 10 mg/day for two years reduced urinary excretion of cross-linked N-telopeptides of type I collagen by approximately 60% and bone-specific alkaline phosphatase by approximately 40%. Similar reductions were observed in a one-year study in men with osteoporosis receiving once weekly FOSAMAX 70 mg. Cholecalciferol Vitamin D is required for normal bone formation. Vitamin D insufficiency is associated with negative calcium balance, leading to increased parathyroid hormone levels and worsening of bone loss associated with osteoporosis. When taken without vitamin D, alendronate is also associated with a reduction in serum calcium concentrations and increased parathyroid hormone levels. In a 15-week trial, 717 postmenopausal women and men, mean age 67 years, with osteoporosis (lumbar spine bone mineral density [BMD] of at least 2.5 standard deviations below the premenopausal mean) were randomized to receive either weekly FOSAMAX PLUS D 70 mg/2800 international units vitamin D or weekly FOSAMAX 70 mg alone with no vitamin D supplementation. Patients who were vitamin D deficient (25-hydroxyvitamin D less than 9 ng/mL) at baseline were excluded. Treatment with FOSAMAX PLUS D 70 mg/2800 international units resulted in a smaller reduction in serum calcium levels (-0.9%) when compared to FOSAMAX 70 mg alone (-1.4%). As well, treatment with FOSAMAX PLUS D 70 mg/2800 international units resulted in a significantly smaller increase in parathyroid hormone levels when compared to FOSAMAX 70 mg alone (14% and 24%, respectively). The sufficiency of patients' vitamin D status is best assessed by measuring 25-hydroxyvitamin D levels. In the 15-week trial mentioned above, baseline 25-hydroxyvitamin D levels were 22.2 ng/mL in the FOSAMAX PLUS D group and 22.1 ng/mL in the FOSAMAX only group. After 15 weeks of treatment, the mean levels were 23.1 ng/mL and 18.4 ng/mL in the FOSAMAX PLUS D and FOSAMAX only groups, respectively. The final levels of 25-hydroxyvitamin D at Week 15 are summarized in Table 4. Table 4: 25-hydroxyvitamin D Levels after Treatment with FOSAMAX PLUS D (70 mg/2800 international units) or FOSAMAX 70 mg at Week 15 Patients who were vitamin D deficient (25-hydroxyvitamin D less than 9 ng/mL) at baseline were excluded. Number (%) of Patients 25-hydroxyvitamin D Ranges (ng/mL) <9 9-14 15-19 20-24 25-29 30-62 FOSAMAX PLUS D (70 mg/2800 international units) (N=357) 4 (1.1) 37 (10.4) 87 (24.4) 84 (23.5) 82 (23.0) 63 (17.7) FOSAMAX 70 mg (N=351) 46 (13.1) 66 (18.8) 108 (30.8) 58 (16.5) 37 (10.5) 36 (10.3) Patients (n=652) who completed the above 15-week trial continued in a 24-week extension in which all received FOSAMAX PLUS D (70 mg/2800 international units) and were randomly assigned to receive either additional once weekly vitamin D 3 2800 international units (Vitamin D 3 5600 international units group) or matching placebo (Vitamin D 3 2800 international units group). After 24 weeks of extended treatment (Week 39 from original baseline), the mean levels of 25-hydroxyvitamin D were 27.9 ng/mL and 25.6 ng/mL in the vitamin D 3 5600 international units group and vitamin D 3 2800 international units group, respectively. The percentage of patients with hypercalciuria at Week 39 was not statistically different between treatment groups. The distribution of the final levels of 25-hydroxyvitamin D at Week 39 is summarized in Table 5. Table 5: 25-hydroxyvitamin D Levels after Treatment with FOSAMAX PLUS D at Week 39 Number (%) of Patients 25-hydroxyvitamin D Ranges (ng/mL) <9 9-14 15-19 20-24 25-29 30-59 FOSAMAX PLUS D (Vitamin D 3 5600 international units group) Patients received FOSAMAX 70 mg or FOSAMAX PLUS D (70 mg/2800 international units) for the 15-week base study followed by FOSAMAX PLUS D (70 mg/2800 international units) and 2800 international units additional vitamin D 3 for the 24-week extension study. (N=321) 0 10 (3.1) 29 (9.0) 79 (24.6) 87 (27.1) 116 (36.1) FOSAMAX PLUS D (Vitamin D 3 2800 international units group) Patients received FOSAMAX 70 mg or FOSAMAX PLUS D (70 mg/2800 international units) for 15-week base study followed by FOSAMAX PLUS D (70 mg/2800 international units) and placebo for the additional vitamin D 3 for 24-week extension study. (N=320) 1 (0.3) 17 (5.3) 56 (17.5) 80 (25.0) 74 (23.1) 92 (28.8)"],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Alendronate Sodium Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast. Oral bioavailability of the 10-mg tablet in men (0.59%) was similar to that in women when administered after an overnight fast and 2 hours before breakfast. In a study, the alendronate in the FOSAMAX PLUS D (70 mg/2800 international units) tablet and the FOSAMAX (alendronate sodium) 70-mg tablet were found to be equally bioavailable. In a separate study, the alendronate in the FOSAMAX PLUS D (70 mg/5600 international units) tablet was found to be equally bioavailable to the alendronate in the FOSAMAX (alendronate sodium) 70-mg tablet. A study examining the effect of timing of a meal on the bioavailability of alendronate was performed in 49 postmenopausal women. Bioavailability was decreased (by approximately 40%) when 10 mg alendronate was administered either 0.5 or 1 hour before a standardized breakfast, when compared to dosing 2 hours before eating. In studies of treatment and prevention of osteoporosis, alendronate was effective when administered at least 30 minutes before breakfast. Bioavailability was negligible whether alendronate was administered with or up to two hours after a standardized breakfast. Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately 60%. Cholecalciferol Following administration of FOSAMAX PLUS D (70 mg/2800 international units) after an overnight fast and two hours before a standard meal, the baseline adjusted mean area under the serum-concentration-time curve (AUC 0-120 hrs ) for vitamin D 3 was 120.7 ng-hr/mL. The baseline adjusted mean maximal serum concentration (C max ) of vitamin D 3 was 4.0 ng/mL, and the baseline adjusted mean time to maximal serum concentration (T max ) was 10.6 hrs. The bioavailability of the 2800 international units vitamin D 3 in FOSAMAX PLUS D is similar to 2800 international units vitamin D 3 administered alone. In a separate study, the baseline adjusted mean AUC 0-80 hrs and baseline adjusted mean C max for vitamin D 3 were 355.6 ng-hr/mL and 10.8 ng/mL, respectively. The baseline adjusted mean T max was 9.2 hrs. The bioavailability of the 5600 international units vitamin D 3 in the FOSAMAX PLUS D is similar to 5600 international units vitamin D 3 administered as two 2800 international units vitamin D 3 tablets. Distribution Alendronate Sodium Preclinical studies (in male rats) show that alendronate transiently distributes to soft tissues following 1 mg/kg intravenous administration but is then rapidly redistributed to bone or excreted in the urine. The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans. Concentrations of drug in plasma following therapeutic oral doses are too low (less than 5 ng/mL) for analytical detection. Protein binding in human plasma is approximately 78%. Cholecalciferol Following absorption, vitamin D 3 enters the blood as part of chylomicrons. Vitamin D 3 is rapidly distributed mostly to the liver where it undergoes metabolism to 25-hydroxyvitamin D 3 , the major storage form. Lesser amounts are distributed to adipose tissue and stored as vitamin D 3 at these sites for later release into the circulation. Circulating vitamin D 3 is bound to vitamin D-binding protein. Metabolism Alendronate Sodium There is no evidence that alendronate is metabolized in animals or humans. Cholecalciferol Vitamin D 3 is rapidly metabolized by hydroxylation in the liver to 25-hydroxyvitamin D 3 , and subsequently metabolized in the kidney to 1,25-dihydroxyvitamin D 3 , which represents the biologically active form. Further hydroxylation occurs prior to elimination. A small percentage of vitamin D 3 undergoes glucuronidation prior to elimination. Excretion Alendronate Sodium Following a single intravenous dose of [ 14 C]alendronate, approximately 50% of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the feces. Following a single 10-mg intravenous dose, the renal clearance of alendronate was 71 mL/min (64, 78; 90% confidence interval [CI]), and systemic clearance did not exceed 200 mL/min. Plasma concentrations fell by more than 95% within 6 hours following intravenous administration. The terminal half-life in humans is estimated to exceed 10 years, probably reflecting release of alendronate from the skeleton. Based on the above, it is estimated that after 10 years of oral treatment with FOSAMAX (10 mg daily) the amount of alendronate released daily from the skeleton is approximately 25% of that absorbed from the gastrointestinal tract. Cholecalciferol When radioactive vitamin D 3 was intravenously administered to healthy subjects, the mean urinary excretion of radioactivity after 48 hours was 2.4% of the administered dose, and the mean fecal excretion of radioactivity after 48 hours was 4.9% of the administered dose. In both cases, the excreted radioactivity was almost exclusively as metabolites of the parent. The mean half-life of baseline adjusted vitamin D 3 in the serum following an oral dose of FOSAMAX PLUS D is approximately 14 hours. Specific Populations Gender: Bioavailability and the fraction of an intravenous dose of alendronate excreted in urine were similar in men and women. Geriatric: Alendronate Sodium Bioavailability and disposition of alendronate (urinary excretion) were similar in elderly and younger patients. No dosage adjustment of alendronate is necessary. Cholecalciferol Dietary requirements of vitamin D 3 are increased in the elderly. Race: Pharmacokinetic differences due to race have not been studied. Renal Impairment: Alendronate Sodium Preclinical studies show that, in rats with kidney failure, increasing amounts of drug are present in plasma, kidney, spleen, and tibia. In healthy controls, drug that is not deposited in bone is rapidly excreted in the urine. No evidence of saturation of bone uptake was found after 3 weeks dosing with cumulative intravenous doses of 35 mg/kg in young male rats. Although no formal renal impairment pharmacokinetic study has been conducted in patients, it is likely that, as in animals, elimination of alendronate via the kidney will be reduced in patients with impaired renal function. Therefore, somewhat greater accumulation of alendronate in bone might be expected in patients with impaired renal function. No dosage adjustment is necessary for patients with creatinine clearance 35 to 60 mL/min. FOSAMAX PLUS D is not recommended for patients with creatinine clearance less than 35 mL/min due to lack of experience with alendronate in renal failure. Cholecalciferol Patients with renal insufficiency will have decreased ability to form the active 1,25-dihydroxyvitamin D 3 metabolite. Hepatic Impairment: Alendronate Sodium As there is evidence that alendronate is not metabolized or excreted in the bile, no studies were conducted in patients with hepatic impairment. No dosage adjustment is necessary. Cholecalciferol Vitamin D 3 may not be adequately absorbed in patients who have malabsorption due to inadequate bile production. Drug Interactions Alendronate Sodium Intravenous ranitidine was shown to double the bioavailability of oral alendronate. The clinical significance of this increased bioavailability and whether similar increases will occur in patients given oral H 2 -antagonists is unknown. In healthy subjects, oral prednisone (20 mg three times daily for five days) did not produce a clinically meaningful change in the oral bioavailability of alendronate (a mean increase ranging from 20 to 44%). Products containing calcium and other multivalent cations are likely to interfere with absorption of alendronate. Cholecalciferol Olestra, mineral oils, orlistat, and bile acid sequestrants (e.g., cholestyramine, colestipol) may impair the absorption of vitamin D. Anticonvulsants, cimetidine, and thiazides may increase the catabolism of vitamin D."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse drug reactions are described elsewhere in the labeling: Upper Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.1) ] Mineral Metabolism [see Warnings and Precautions (5.2) ] Musculoskeletal Pain [see Warnings and Precautions (5.3) ] Osteonecrosis of the Jaw [see Warnings and Precautions (5.4) ] Atypical Fractures Including Femoral Fractures [see Warnings and Precautions (5.5) ] Renal Impairment [see Warnings and Precautions (5.6) ] Most common adverse reactions (greater than or equal to 3%) for alendronate are: abdominal pain, acid regurgitation, constipation, diarrhea, dyspepsia, musculoskeletal pain, nausea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Organon LLC, a subsidiary of Organon & Co., at 1-844-674-3200 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. FOSAMAX Treatment of Osteoporosis in Postmenopausal Women FOSAMAX Daily The safety of FOSAMAX in the treatment of postmenopausal osteoporosis was assessed in four clinical trials that enrolled 7453 women aged 44-84 years. Study 1 and Study 2 were identically designed, three-year, placebo-controlled, double-blind, multicenter studies (United States and Multinational; n=994); Study 3 was the three-year vertebral fracture cohort of the Fracture Intervention Trial [FIT] (n=2027); and Study 4 was the four-year clinical fracture cohort of FIT (n=4432). Overall, 3620 patients were exposed to placebo and 3432 patients exposed to FOSAMAX. Patients with pre-existing gastrointestinal disease and concomitant use of non-steroidal anti-inflammatory drugs were included in these clinical trials. In Study 1 and Study 2 all women received 500 mg elemental calcium as carbonate. In Study 3 and Study 4 all women with dietary calcium intake less than 1000 mg per day received 500 mg calcium and 250 international units Vitamin D per day. Among patients treated with alendronate 10 mg or placebo in Study 1 and Study 2, and all patients in Study 3 and Study 4, the incidence of all-cause mortality was 1.8% in the placebo group and 1.8% in the FOSAMAX group. The incidence of serious adverse event was 30.7% in the placebo group and 30.9% in the FOSAMAX group. The percentage of patients who discontinued the study due to any clinical adverse event was 9.5% in the placebo group and 8.9% in the FOSAMAX group. Adverse reactions from these studies considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 1% of patients treated with either FOSAMAX or placebo are presented in Table 1. Table 1: Osteoporosis Treatment Studies in Postmenopausal Women Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to 1% of Patients United States/Multinational Studies Fracture Intervention Trial FOSAMAX 10 mg/day for three years % (n=196) Placebo % (n=397) FOSAMAX 5 mg/day for 2 years and 10 mg/day for either 1 or 2 additional years % (n=3236) Placebo % (n=3223) Gastrointestinal abdominal pain nausea dyspepsia constipation diarrhea flatulence acid regurgitation esophageal ulcer vomiting dysphagia abdominal distention gastritis 6.6 3.6 3.6 3.1 3.1 2.6 2.0 1.5 1.0 1.0 1.0 0.5 4.8 4.0 3.5 1.8 1.8 0.5 4.3 0.0 1.5 0.0 0.8 1.3 1.5 1.1 1.1 0.0 0.6 0.2 1.1 0.1 0.2 0.1 0.0 0.6 1.5 1.5 1.2 0.2 0.3 0.3 0.9 0.1 0.3 0.1 0.0 0.7 Musculoskeletal musculoskeletal (bone, muscle or joint) pain muscle cramp 4.1 0.0 2.5 1.0 0.4 0.2 0.3 0.1 Nervous System/Psychiatric headache dizziness 2.6 0.0 1.5 1.0 0.2 0.0 0.2 0.1 Special Senses taste perversion 0.5 1.0 0.1 0.0 Rash and erythema have occurred. Gastrointestinal Adverse Reactions: One patient treated with FOSAMAX (10 mg/day), who had a history of peptic ulcer disease and gastrectomy and who was taking concomitant aspirin, developed an anastomotic ulcer with mild hemorrhage, which was considered drug related. Aspirin and FOSAMAX were discontinued and the patient recovered. In the Study 1 and Study 2 populations, 49-54% had a history of gastrointestinal disorders at baseline, and 54-89% used nonsteroidal anti-inflammatory drugs or aspirin at some time during the studies. [See Warnings and Precautions (5.1) .] Laboratory Test Findings: In double-blind, multicenter, controlled studies, asymptomatic, mild, and transient decreases in serum calcium and phosphate were observed in approximately 18% and 10%, respectively, of patients taking FOSAMAX versus approximately 12% and 3% of those taking placebo. However, the incidences of decreases in serum calcium to less than 8.0 mg/dL (2.0 mM) and serum phosphate to less than or equal to 2.0 mg/dL (0.65 mM) were similar in both treatment groups. FOSAMAX Once-Weekly The safety of FOSAMAX 70 mg once weekly for the treatment of postmenopausal osteoporosis was assessed in a one-year, double-blind, multicenter study comparing FOSAMAX 70 mg once weekly and FOSAMAX 10 mg daily. The overall safety and tolerability profiles of once weekly FOSAMAX 70 mg and FOSAMAX 10 mg daily were similar. The adverse reactions considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 1% of patients in either treatment group are presented in Table 2. Table 2: Osteoporosis Treatment Studies in Postmenopausal Women Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to 1% of Patients Once Weekly FOSAMAX 70 mg % (n=519) FOSAMAX 10 mg/day % (n=370) Gastrointestinal abdominal pain dyspepsia acid regurgitation nausea abdominal distention constipation flatulence gastritis gastric ulcer 3.7 2.7 1.9 1.9 1.0 0.8 0.4 0.2 0.0 3.0 2.2 2.4 2.4 1.4 1.6 1.6 1.1 1.1 Musculoskeletal musculoskeletal (bone, muscle, joint) pain muscle cramp 2.9 0.2 3.2 1.1 Concomitant Use With Estrogen/Hormone Replacement Therapy In two studies (of one and two years' duration) of postmenopausal osteoporotic women (total: n=853), the safety and tolerability profile of combined treatment with FOSAMAX 10 mg once daily and estrogen ± progestin (n=354) was consistent with those of the individual treatments. Osteoporosis in Men In two placebo-controlled, double-blind, multicenter studies in men (a two-year study of FOSAMAX 10 mg/day and a one-year study of once weekly FOSAMAX 70 mg) the rates of discontinuation of therapy due to any clinical adverse event were 2.7% for FOSAMAX 10 mg/day vs. 10.5% for placebo, and 6.4% for once weekly FOSAMAX 70 mg vs. 8.6% for placebo. The adverse reactions considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to 2% of patients treated with either FOSAMAX or placebo are presented in Table 3. Table 3: Osteoporosis Studies in Men Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to 2% of Patients Two-year Study One-year Study FOSAMAX 10 mg/day % (n=146) Placebo % (n=95) Once Weekly FOSAMAX 70 mg % (n=109) Placebo % (n=58) Gastrointestinal acid regurgitation flatulence gastroesophageal reflux disease dyspepsia diarrhea abdominal pain nausea 4.1 4.1 0.7 3.4 1.4 2.1 2.1 3.2 1.1 3.2 0.0 1.1 1.1 0.0 0.0 0.0 2.8 2.8 2.8 0.9 0.0 0.0 0.0 0.0 1.7 0.0 3.4 0.0 FOSAMAX PLUS D In a fifteen-week double-blind, multinational study in osteoporotic postmenopausal women (n=682) and men (n=35), the safety profile of FOSAMAX PLUS D (70 mg/2800 international units) was similar to that of FOSAMAX once weekly 70 mg. In the 24-week double-blind extension study in women (n=619) and men (n=33), the safety profile of FOSAMAX PLUS D (70 mg/2800 international units) administered with an additional 2800 international units vitamin D 3 was similar to that of FOSAMAX PLUS D (70 mg/2800 international units). 6.2 Post-Marketing Experience The following adverse reactions have been identified during post-approval use of FOSAMAX, FOSAMAX PLUS D, or bisphosphonate products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Body as a Whole: hypersensitivity reactions including urticaria and angioedema. Transient symptoms of myalgia, malaise, asthenia and rarely, fever have been reported with alendronate, typically in association with initiation of treatment. Symptomatic hypocalcemia has occurred, generally in association with predisposing conditions. Peripheral edema. Gastrointestinal: esophagitis, esophageal erosions, esophageal ulcers, esophageal stricture or perforation, and oropharyngeal ulceration. Gastric or duodenal ulcers, some severe and with complications have also been reported [see Dosage and Administration (2.3) and Warnings and Precautions (5.1) ] . Localized osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection with delayed healing, has been reported [see Warnings and Precautions (5.4) ] . Musculoskeletal: bone, joint, and/or muscle pain, occasionally severe, and incapacitating [see Warnings and Precautions (5.3) ] ; joint swelling; low-energy femoral shaft and subtrochanteric fractures, and atypical fractures of other bones [see Warnings and Precautions (5.5) ] . Nervous System: dizziness and vertigo. Pulmonary: acute asthma exacerbations. Skin: rash (occasionally with photosensitivity), pruritus, alopecia, severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Special Senses: uveitis, scleritis or episcleritis. Cholesteatoma of the external auditory canal (focal osteonecrosis)."],"contraindications":["4 CONTRAINDICATIONS FOSAMAX PLUS D is contraindicated in patients with the following conditions: Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia [see Warnings and Precautions (5.1) ] Inability to stand or sit upright for at least 30 minutes [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) ] Hypocalcemia [see Warnings and Precautions (5.2) ] Hypersensitivity to any component of this product. Hypersensitivity reactions including urticaria and angioedema have been reported [see Adverse Reactions (6.2) ] . Abnormalities of the esophagus which delay emptying such as stricture or achalasia ( 4 , 5.1 ) Inability to stand/sit upright for at least 30 minutes ( 2.3 , 4 , 5.1 ) Hypocalcemia ( 4 , 5.2 ) Hypersensitivity to any component of this product ( 4 , 6.2 )"],"drug_interactions":["7 DRUG INTERACTIONS Calcium supplements/antacids or oral medications containing multivalent cations interfere with absorption of alendronate. ( 2.3 , 7.1 ) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. ( 7.2 , 7.3 ) Some drugs may impair the absorption or increase the catabolism of cholecalciferol (vitamin D 3 ). Additional vitamin D supplementation should be considered. ( 7.4 , 7.5 , 12.3 ) 7.1 Calcium Supplements/Antacids Co-administration of FOSAMAX PLUS D and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of alendronate. Therefore, instruct patients to wait at least one-half hour after taking FOSAMAX PLUS D before taking any other oral medications. 7.2 Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of FOSAMAX greater than 10 mg and aspirin-containing products. 7.3 Nonsteroidal Anti-Inflammatory Drugs FOSAMAX PLUS D may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). In a 3-year, controlled, clinical study (n=2027) during which a majority of patients received concomitant NSAIDs, the incidence of upper gastrointestinal adverse events was similar in patients taking FOSAMAX 5 or 10 mg/day compared to those taking placebo. However, since NSAID use is associated with gastrointestinal irritation, caution should be used during concomitant use with FOSAMAX PLUS D. 7.4 Drugs that May Impair the Absorption of Cholecalciferol Olestra, mineral oils, orlistat, and bile acid sequestrants (e.g., cholestyramine, colestipol) may impair the absorption of vitamin D. Additional vitamin D supplementation should be considered [see Clinical Pharmacology (12.3) ] . 7.5 Drugs that May Increase the Catabolism of Cholecalciferol Anticonvulsants, cimetidine, and thiazides may increase the catabolism of vitamin D. Additional vitamin D supplementation should be considered [see Clinical Pharmacology (12.3) ] ."],"mechanism_of_action":["12.1 Mechanism of Action Alendronate Sodium Animal studies have indicated the following mode of action. At the cellular level, alendronate shows preferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active resorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [ 3 H]alendronate in bone showed about 10-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones examined 6 and 49 days after [ 3 H]alendronate administration in rats and mice, respectively, showed that normal bone was formed on top of the alendronate, which was incorporated inside the matrix. While incorporated in bone matrix, alendronate is not pharmacologically active. Thus, alendronate must be continuously administered to suppress osteoclasts on newly formed resorption surfaces. Histomorphometry in baboons and rats showed that alendronate treatment reduces bone turnover (i.e., the number of sites at which bone is remodeled). In addition, bone formation exceeds bone resorption at these remodeling sites, leading to progressive gains in bone mass. Cholecalciferol Vitamin D 3 is produced in the skin by photochemical conversion of 7-dehydrocholesterol to previtamin D 3 by ultraviolet light. This is followed by non-enzymatic isomerization to vitamin D 3 . In the absence of adequate sunlight exposure, vitamin D 3 is an essential dietary nutrient. Vitamin D 3 in skin and dietary vitamin D 3 (absorbed into chylomicrons) is converted to 25-hydroxyvitamin D 3 in the liver. Conversion to the active calcium-mobilizing hormone 1,25-dihydroxyvitamin D 3 (calcitriol) in the kidney is stimulated by both parathyroid hormone and hypophosphatemia. The principal action of 1,25-dihydroxyvitamin D 3 is to increase intestinal absorption of both calcium and phosphate as well as regulate serum calcium, renal calcium and phosphate excretion, bone formation and bone resorption. Vitamin D is required for normal bone formation. Vitamin D insufficiency develops when both sunlight exposure and dietary intake are inadequate. Insufficiency is associated with negative calcium balance, increased parathyroid hormone levels, bone loss, and increased risk of skeletal fracture. In severe cases, deficiency results in more severe hyperparathyroidism, hypophosphatemia, proximal muscle weakness, bone pain and osteomalacia."],"recent_major_changes":["Warnings and Precautions, Atypical Fractures Including Femoral Fractures ( 5.5 ) 2/2026"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Alendronate Sodium Animal studies have indicated the following mode of action. At the cellular level, alendronate shows preferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active resorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [ 3 H]alendronate in bone showed about 10-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones examined 6 and 49 days after [ 3 H]alendronate administration in rats and mice, respectively, showed that normal bone was formed on top of the alendronate, which was incorporated inside the matrix. While incorporated in bone matrix, alendronate is not pharmacologically active. Thus, alendronate must be continuously administered to suppress osteoclasts on newly formed resorption surfaces. Histomorphometry in baboons and rats showed that alendronate treatment reduces bone turnover (i.e., the number of sites at which bone is remodeled). In addition, bone formation exceeds bone resorption at these remodeling sites, leading to progressive gains in bone mass. Cholecalciferol Vitamin D 3 is produced in the skin by photochemical conversion of 7-dehydrocholesterol to previtamin D 3 by ultraviolet light. This is followed by non-enzymatic isomerization to vitamin D 3 . In the absence of adequate sunlight exposure, vitamin D 3 is an essential dietary nutrient. Vitamin D 3 in skin and dietary vitamin D 3 (absorbed into chylomicrons) is converted to 25-hydroxyvitamin D 3 in the liver. Conversion to the active calcium-mobilizing hormone 1,25-dihydroxyvitamin D 3 (calcitriol) in the kidney is stimulated by both parathyroid hormone and hypophosphatemia. The principal action of 1,25-dihydroxyvitamin D 3 is to increase intestinal absorption of both calcium and phosphate as well as regulate serum calcium, renal calcium and phosphate excretion, bone formation and bone resorption. Vitamin D is required for normal bone formation. Vitamin D insufficiency develops when both sunlight exposure and dietary intake are inadequate. Insufficiency is associated with negative calcium balance, increased parathyroid hormone levels, bone loss, and increased risk of skeletal fracture. In severe cases, deficiency results in more severe hyperparathyroidism, hypophosphatemia, proximal muscle weakness, bone pain and osteomalacia. 12.2 Pharmacodynamics Alendronate Sodium Alendronate is a bisphosphonate that binds to bone hydroxyapatite and specifically inhibits the activity of osteoclasts, the bone-resorbing cells. Alendronate reduces bone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled during bone turnover. Daily oral doses of alendronate (5, 20, and 40 mg for six weeks) in postmenopausal women produced biochemical changes indicative of dose-dependent inhibition of bone resorption, including decreases in urinary calcium and urinary markers of bone collagen degradation (such as deoxypyridinoline and cross-linked N-telopeptides of type I collagen). These biochemical changes tended to return toward baseline values as early as 3 weeks following the discontinuation of therapy with alendronate and did not differ from placebo after 7 months. Long-term treatment of osteoporosis with FOSAMAX 10 mg/day (for up to five years) reduced urinary excretion of markers of bone resorption, deoxypyridinoline and cross-linked N-telopeptides of type l collagen, by approximately 50% and 70%, respectively, to reach levels similar to those seen in healthy premenopausal women. The decrease in the rate of bone resorption indicated by these markers was evident as early as one month and at three to six months reached a plateau that was maintained for the entire duration of treatment with FOSAMAX. In osteoporosis treatment studies FOSAMAX 10 mg/day decreased the markers of bone formation, osteocalcin and bone specific alkaline phosphatase by approximately 50%, and total serum alkaline phosphatase by approximately 25 to 30% to reach a plateau after 6 to 12 months. Similar reductions in the rate of bone turnover were observed in postmenopausal women during one-year studies with once weekly FOSAMAX 70 mg for the treatment of osteoporosis. These data indicate that the rate of bone turnover reached a new steady-state, despite the progressive increase in the total amount of alendronate deposited within bone. As a result of inhibition of bone resorption, asymptomatic reductions in serum calcium and phosphate concentrations were also observed following treatment with FOSAMAX. In the long-term studies, reductions from baseline in serum calcium (approximately 2%) and phosphate (approximately 4 to 6%) were evident the first month after the initiation of FOSAMAX 10 mg. No further decreases in serum calcium were observed for the five-year duration of treatment; however, serum phosphate returned toward prestudy levels during years three through five. In one-year studies with once weekly FOSAMAX 70 mg, similar reductions were observed at 6 and 12 months. The reduction in serum phosphate may reflect not only the positive bone mineral balance due to FOSAMAX but also a decrease in renal phosphate reabsorption. Osteoporosis in Men Treatment of men with osteoporosis with FOSAMAX 10 mg/day for two years reduced urinary excretion of cross-linked N-telopeptides of type I collagen by approximately 60% and bone-specific alkaline phosphatase by approximately 40%. Similar reductions were observed in a one-year study in men with osteoporosis receiving once weekly FOSAMAX 70 mg. Cholecalciferol Vitamin D is required for normal bone formation. Vitamin D insufficiency is associated with negative calcium balance, leading to increased parathyroid hormone levels and worsening of bone loss associated with osteoporosis. When taken without vitamin D, alendronate is also associated with a reduction in serum calcium concentrations and increased parathyroid hormone levels. In a 15-week trial, 717 postmenopausal women and men, mean age 67 years, with osteoporosis (lumbar spine bone mineral density [BMD] of at least 2.5 standard deviations below the premenopausal mean) were randomized to receive either weekly FOSAMAX PLUS D 70 mg/2800 international units vitamin D or weekly FOSAMAX 70 mg alone with no vitamin D supplementation. Patients who were vitamin D deficient (25-hydroxyvitamin D less than 9 ng/mL) at baseline were excluded. Treatment with FOSAMAX PLUS D 70 mg/2800 international units resulted in a smaller reduction in serum calcium levels (-0.9%) when compared to FOSAMAX 70 mg alone (-1.4%). As well, treatment with FOSAMAX PLUS D 70 mg/2800 international units resulted in a significantly smaller increase in parathyroid hormone levels when compared to FOSAMAX 70 mg alone (14% and 24%, respectively). The sufficiency of patients' vitamin D status is best assessed by measuring 25-hydroxyvitamin D levels. In the 15-week trial mentioned above, baseline 25-hydroxyvitamin D levels were 22.2 ng/mL in the FOSAMAX PLUS D group and 22.1 ng/mL in the FOSAMAX only group. After 15 weeks of treatment, the mean levels were 23.1 ng/mL and 18.4 ng/mL in the FOSAMAX PLUS D and FOSAMAX only groups, respectively. The final levels of 25-hydroxyvitamin D at Week 15 are summarized in Table 4. Table 4: 25-hydroxyvitamin D Levels after Treatment with FOSAMAX PLUS D (70 mg/2800 international units) or FOSAMAX 70 mg at Week 15 Patients who were vitamin D deficient (25-hydroxyvitamin D less than 9 ng/mL) at baseline were excluded. Number (%) of Patients 25-hydroxyvitamin D Ranges (ng/mL) <9 9-14 15-19 20-24 25-29 30-62 FOSAMAX PLUS D (70 mg/2800 international units) (N=357) 4 (1.1) 37 (10.4) 87 (24.4) 84 (23.5) 82 (23.0) 63 (17.7) FOSAMAX 70 mg (N=351) 46 (13.1) 66 (18.8) 108 (30.8) 58 (16.5) 37 (10.5) 36 (10.3) Patients (n=652) who completed the above 15-week trial continued in a 24-week extension in which all received FOSAMAX PLUS D (70 mg/2800 international units) and were randomly assigned to receive either additional once weekly vitamin D 3 2800 international units (Vitamin D 3 5600 international units group) or matching placebo (Vitamin D 3 2800 international units group). After 24 weeks of extended treatment (Week 39 from original baseline), the mean levels of 25-hydroxyvitamin D were 27.9 ng/mL and 25.6 ng/mL in the vitamin D 3 5600 international units group and vitamin D 3 2800 international units group, respectively. The percentage of patients with hypercalciuria at Week 39 was not statistically different between treatment groups. The distribution of the final levels of 25-hydroxyvitamin D at Week 39 is summarized in Table 5. Table 5: 25-hydroxyvitamin D Levels after Treatment with FOSAMAX PLUS D at Week 39 Number (%) of Patients 25-hydroxyvitamin D Ranges (ng/mL) <9 9-14 15-19 20-24 25-29 30-59 FOSAMAX PLUS D (Vitamin D 3 5600 international units group) Patients received FOSAMAX 70 mg or FOSAMAX PLUS D (70 mg/2800 international units) for the 15-week base study followed by FOSAMAX PLUS D (70 mg/2800 international units) and 2800 international units additional vitamin D 3 for the 24-week extension study. (N=321) 0 10 (3.1) 29 (9.0) 79 (24.6) 87 (27.1) 116 (36.1) FOSAMAX PLUS D (Vitamin D 3 2800 international units group) Patients received FOSAMAX 70 mg or FOSAMAX PLUS D (70 mg/2800 international units) for 15-week base study followed by FOSAMAX PLUS D (70 mg/2800 international units) and placebo for the additional vitamin D 3 for 24-week extension study. (N=320) 1 (0.3) 17 (5.3) 56 (17.5) 80 (25.0) 74 (23.1) 92 (28.8) 12.3 Pharmacokinetics Absorption Alendronate Sodium Relative to an intravenous reference dose, the mean oral bioavailability of alendronate in women was 0.64% for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardized breakfast. Oral bioavailability of the 10-mg tablet in men (0.59%) was similar to that in women when administered after an overnight fast and 2 hours before breakfast. In a study, the alendronate in the FOSAMAX PLUS D (70 mg/2800 international units) tablet and the FOSAMAX (alendronate sodium) 70-mg tablet were found to be equally bioavailable. In a separate study, the alendronate in the FOSAMAX PLUS D (70 mg/5600 international units) tablet was found to be equally bioavailable to the alendronate in the FOSAMAX (alendronate sodium) 70-mg tablet. A study examining the effect of timing of a meal on the bioavailability of alendronate was performed in 49 postmenopausal women. Bioavailability was decreased (by approximately 40%) when 10 mg alendronate was administered either 0.5 or 1 hour before a standardized breakfast, when compared to dosing 2 hours before eating. In studies of treatment and prevention of osteoporosis, alendronate was effective when administered at least 30 minutes before breakfast. Bioavailability was negligible whether alendronate was administered with or up to two hours after a standardized breakfast. Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately 60%. Cholecalciferol Following administration of FOSAMAX PLUS D (70 mg/2800 international units) after an overnight fast and two hours before a standard meal, the baseline adjusted mean area under the serum-concentration-time curve (AUC 0-120 hrs ) for vitamin D 3 was 120.7 ng-hr/mL. The baseline adjusted mean maximal serum concentration (C max ) of vitamin D 3 was 4.0 ng/mL, and the baseline adjusted mean time to maximal serum concentration (T max ) was 10.6 hrs. The bioavailability of the 2800 international units vitamin D 3 in FOSAMAX PLUS D is similar to 2800 international units vitamin D 3 administered alone. In a separate study, the baseline adjusted mean AUC 0-80 hrs and baseline adjusted mean C max for vitamin D 3 were 355.6 ng-hr/mL and 10.8 ng/mL, respectively. The baseline adjusted mean T max was 9.2 hrs. The bioavailability of the 5600 international units vitamin D 3 in the FOSAMAX PLUS D is similar to 5600 international units vitamin D 3 administered as two 2800 international units vitamin D 3 tablets. Distribution Alendronate Sodium Preclinical studies (in male rats) show that alendronate transiently distributes to soft tissues following 1 mg/kg intravenous administration but is then rapidly redistributed to bone or excreted in the urine. The mean steady-state volume of distribution, exclusive of bone, is at least 28 L in humans. Concentrations of drug in plasma following therapeutic oral doses are too low (less than 5 ng/mL) for analytical detection. Protein binding in human plasma is approximately 78%. Cholecalciferol Following absorption, vitamin D 3 enters the blood as part of chylomicrons. Vitamin D 3 is rapidly distributed mostly to the liver where it undergoes metabolism to 25-hydroxyvitamin D 3 , the major storage form. Lesser amounts are distributed to adipose tissue and stored as vitamin D 3 at these sites for later release into the circulation. Circulating vitamin D 3 is bound to vitamin D-binding protein. Metabolism Alendronate Sodium There is no evidence that alendronate is metabolized in animals or humans. Cholecalciferol Vitamin D 3 is rapidly metabolized by hydroxylation in the liver to 25-hydroxyvitamin D 3 , and subsequently metabolized in the kidney to 1,25-dihydroxyvitamin D 3 , which represents the biologically active form. Further hydroxylation occurs prior to elimination. A small percentage of vitamin D 3 undergoes glucuronidation prior to elimination. Excretion Alendronate Sodium Following a single intravenous dose of [ 14 C]alendronate, approximately 50% of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the feces. Following a single 10-mg intravenous dose, the renal clearance of alendronate was 71 mL/min (64, 78; 90% confidence interval [CI]), and systemic clearance did not exceed 200 mL/min. Plasma concentrations fell by more than 95% within 6 hours following intravenous administration. The terminal half-life in humans is estimated to exceed 10 years, probably reflecting release of alendronate from the skeleton. Based on the above, it is estimated that after 10 years of oral treatment with FOSAMAX (10 mg daily) the amount of alendronate released daily from the skeleton is approximately 25% of that absorbed from the gastrointestinal tract. Cholecalciferol When radioactive vitamin D 3 was intravenously administered to healthy subjects, the mean urinary excretion of radioactivity after 48 hours was 2.4% of the administered dose, and the mean fecal excretion of radioactivity after 48 hours was 4.9% of the administered dose. In both cases, the excreted radioactivity was almost exclusively as metabolites of the parent. The mean half-life of baseline adjusted vitamin D 3 in the serum following an oral dose of FOSAMAX PLUS D is approximately 14 hours. Specific Populations Gender: Bioavailability and the fraction of an intravenous dose of alendronate excreted in urine were similar in men and women. Geriatric: Alendronate Sodium Bioavailability and disposition of alendronate (urinary excretion) were similar in elderly and younger patients. No dosage adjustment of alendronate is necessary. Cholecalciferol Dietary requirements of vitamin D 3 are increased in the elderly. Race: Pharmacokinetic differences due to race have not been studied. Renal Impairment: Alendronate Sodium Preclinical studies show that, in rats with kidney failure, increasing amounts of drug are present in plasma, kidney, spleen, and tibia. In healthy controls, drug that is not deposited in bone is rapidly excreted in the urine. No evidence of saturation of bone uptake was found after 3 weeks dosing with cumulative intravenous doses of 35 mg/kg in young male rats. Although no formal renal impairment pharmacokinetic study has been conducted in patients, it is likely that, as in animals, elimination of alendronate via the kidney will be reduced in patients with impaired renal function. Therefore, somewhat greater accumulation of alendronate in bone might be expected in patients with impaired renal function. No dosage adjustment is necessary for patients with creatinine clearance 35 to 60 mL/min. FOSAMAX PLUS D is not recommended for patients with creatinine clearance less than 35 mL/min due to lack of experience with alendronate in renal failure. Cholecalciferol Patients with renal insufficiency will have decreased ability to form the active 1,25-dihydroxyvitamin D 3 metabolite. Hepatic Impairment: Alendronate Sodium As there is evidence that alendronate is not metabolized or excreted in the bile, no studies were conducted in patients with hepatic impairment. No dosage adjustment is necessary. Cholecalciferol Vitamin D 3 may not be adequately absorbed in patients who have malabsorption due to inadequate bile production. Drug Interactions Alendronate Sodium Intravenous ranitidine was shown to double the bioavailability of oral alendronate. The clinical significance of this increased bioavailability and whether similar increases will occur in patients given oral H 2 -antagonists is unknown. In healthy subjects, oral prednisone (20 mg three times daily for five days) did not produce a clinically meaningful change in the oral bioavailability of alendronate (a mean increase ranging from 20 to 44%). Products containing calcium and other multivalent cations are likely to interfere with absorption of alendronate. Cholecalciferol Olestra, mineral oils, orlistat, and bile acid sequestrants (e.g., cholestyramine, colestipol) may impair the absorption of vitamin D. Anticonvulsants, cimetidine, and thiazides may increase the catabolism of vitamin D."],"indications_and_usage":["1 INDICATIONS AND USAGE FOSAMAX PLUS D is a combination of a bisphosphonate and vitamin D indicated for: Treatment of osteoporosis in postmenopausal women ( 1.1 ) Treatment to increase bone mass in men with osteoporosis ( 1.2 ) Limitations of use : FOSAMAX PLUS D alone should not be used to treat vitamin D deficiency. ( 1.3 ) Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. ( 1.3 ) 1.1 Treatment of Osteoporosis in Postmenopausal Women FOSAMAX ® PLUS D is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, FOSAMAX PLUS D increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [See Clinical Studies (14.1) .] 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis FOSAMAX PLUS D is indicated for treatment to increase bone mass in men with osteoporosis [see Clinical Studies (14.2) ] . 1.3 Important Limitations of Use FOSAMAX PLUS D alone should not be used to treat vitamin D deficiency. The optimal duration of use has not been determined. The safety and effectiveness of FOSAMAX PLUS D for the treatment of osteoporosis are based on clinical data of four years duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue if new or worsening symptoms occur. ( 5.1 ) Hypocalcemia can worsen and must be corrected prior to use. ( 5.2 ) Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop. ( 5.3 ) Osteonecrosis of the Jaw has been reported. ( 5.4 ) Atypical Fractures Including Femoral Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. Risk/benefit of continuing bisphosphonate therapy should be re-evaluated in these patients and interruption of bisphosphonate therapy should be considered. ( 5.5 ) 5.1 Upper Gastrointestinal Adverse Reactions FOSAMAX PLUS D, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects and a potential for worsening of the underlying disease, caution should be used when FOSAMAX PLUS D is given to patients with active upper gastrointestinal problems (such as known Barrett's esophagus, dysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers). Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and rarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates including FOSAMAX PLUS D. In some cases these have been severe and required hospitalization. Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be instructed to discontinue FOSAMAX PLUS D and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. The risk of severe esophageal adverse experiences appears to be greater in patients who lie down after taking oral bisphosphonates including FOSAMAX PLUS D and/or who fail to swallow oral bisphosphonates including FOSAMAX PLUS D with the recommended full glass (6-8 ounces) of water, and/or who continue to take oral bisphosphonates including FOSAMAX PLUS D after developing symptoms suggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [see Dosage and Administration (2.3) ] . In patients who cannot comply with dosing instructions due to mental disability, therapy with FOSAMAX PLUS D should be used under appropriate supervision. There have been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications, although no increased risk was observed in controlled clinical trials [see Adverse Reactions (6.2) ] . 5.2 Mineral Metabolism Alendronate Sodium Hypocalcemia must be corrected before initiating therapy with FOSAMAX PLUS D [see Contraindications (4) ] . Other disorders affecting mineral metabolism (such as vitamin D deficiency) should also be effectively treated. In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with FOSAMAX PLUS D. Presumably due to the effects of alendronate on increasing bone mineral, small, asymptomatic decreases in serum calcium and phosphate may occur. Cholecalciferol FOSAMAX PLUS D alone should not be used to treat vitamin D deficiency (commonly defined as 25-hydroxyvitamin D level below 9 ng/mL). Patients at increased risk for vitamin D insufficiency may require higher doses of vitamin D supplementation [see Dosage and Administration (2.4) ] . Patients with gastrointestinal malabsorption syndromes may require higher doses of vitamin D supplementation and measurement of 25-hydroxyvitamin D should be considered. Vitamin D 3 supplementation may worsen hypercalcemia and/or hypercalciuria when administered to patients with diseases associated with unregulated overproduction of 1,25 dihydroxyvitamin D (e.g., leukemia, lymphoma, sarcoidosis). Urine and serum calcium should be monitored in these patients. 5.3 Musculoskeletal Pain In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients taking bisphosphonates that are approved for the prevention and treatment of osteoporosis [see Adverse Reactions (6.2) ] . This category of drugs includes alendronate. Most of the patients were postmenopausal women. The time to onset of symptoms varied from one day to several months after starting the drug. Discontinue use if severe symptoms develop. Most patients had relief of symptoms after stopping. A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate. In placebo-controlled clinical studies of FOSAMAX, the percentages of patients with these symptoms were similar in the FOSAMAX and placebo groups. 5.4 Osteonecrosis of the Jaw Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including FOSAMAX PLUS D. Known risk factors for osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures). The risk of ONJ may increase with duration of exposure to bisphosphonates. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ. Clinical judgment of the treating physician and/or oral surgeon should guide the management plan of each patient based on individual benefit/risk assessment. Patients who develop osteonecrosis of the jaw while on bisphosphonate therapy should receive care by an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition. Discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment. 5.5 Atypical Fractures Including Femoral Fractures Atypical, low-energy, or low trauma fractures of the femoral shaft have been reported during treatment with bisphosphonates, including alendronate, in patients with osteoporosis. Atypical femur and other fractures most commonly occur with minimal or no trauma to the affected area. These fractures occurred anywhere in the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are transverse or short oblique in orientation without evidence of comminution. Atypical fractures of other bones have also been reported. They may be bilateral. These fractures can also occur in osteoporotic patients who have not been treated with bisphosphonates. Concomitant treatment with glucocorticoid may also induce these fractures. Prodromal pain in the affected area, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture occurs was reported by patients. Any patient with a history of bisphosphonate exposure who presents with thigh or groin pain should be suspected of having an atypical fracture and should be evaluated to rule out an incomplete femur fracture. Bony pain in other locations should also be considered for evaluation of atypical fracture. Patients presenting with an atypical fracture should also be assessed for symptoms and signs of fracture in the contralateral limb. Risk/benefit of continuing bisphosphonate therapy should be re-evaluated in these patients and interruption of bisphosphonate therapy should be considered. 5.6 Renal Impairment FOSAMAX PLUS D is not recommended for patients with creatinine clearance less than 35 mL/min."],"clinical_studies_table":["<table width=\"675.000\" ID=\"id_29f5e519-213c-4110-8f25-2e9503284f39\"><caption ID=\"id_17812444-51c9-4a6e-81ce-f602444a2586\">Table 6: Effect of FOSAMAX on Fracture Incidence in the Three-Year Study of FIT (patients with vertebral fracture at baseline)</caption><col width=\"48%\"/><col width=\"12%\"/><col width=\"13%\"/><col width=\"14%\"/><col width=\"13%\"/><thead><tr ID=\"id_6337d143-0707-45ab-981f-222bb16b9355\"><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"/><td align=\"center\" valign=\"top\" colspan=\"3\" styleCode=\"Toprule\">Percent of Patients</td><td align=\"left\" valign=\"top\"/></tr><tr ID=\"id_ae3edffc-8cd1-4c99-9f63-2f1fade79470\"><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">  FOSAMAX (n=1022)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">  Placebo (n=1005)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">Absolute Reduction in Fracture Incidence </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">Relative Reduction in Fracture  Risk %</td></tr></thead><tbody><tr ID=\"id_79173e32-fe4b-4799-adf4-4eed097e3ca1\"><td align=\"left\" valign=\"top\" styleCode=\"Toprule\">Patients with:</td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"/><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"/><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"/><td align=\"center\" valign=\"top\"/></tr><tr ID=\"id_20f78f5f-f4df-4779-9de0-2875941e45b1\"><td align=\"left\" valign=\"top\">Vertebral fractures (diagnosed by X-ray)<footnote ID=\"id-aa440cec-d651-4d7f-a382-bf56a3201246\">Number evaluable for vertebral fractures: FOSAMAX, n=984; placebo, n=966</footnote></td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/></tr><tr ID=\"id_3b041cc2-053c-4012-8a64-0730918a31c3\"><td align=\"left\" valign=\"top\"> &#x2265;1 new vertebral fracture</td><td align=\"center\" valign=\"top\">7.9</td><td align=\"center\" valign=\"top\">15.0</td><td align=\"center\" valign=\"top\">7.1</td><td align=\"center\" valign=\"top\">47<footnote ID=\"id-8976aa79-124d-4e0c-987b-07d57ad19a23\">p&lt;0.001</footnote></td></tr><tr ID=\"id_edb82957-3f5e-4f4e-ae82-76d3bfa339d7\"><td align=\"left\" valign=\"top\"> &#x2265;2 new vertebral fractures</td><td align=\"center\" valign=\"top\">0.5</td><td align=\"center\" valign=\"top\">4.9</td><td align=\"center\" valign=\"top\">4.4</td><td align=\"center\" valign=\"top\">90<footnoteRef IDREF=\"id-8976aa79-124d-4e0c-987b-07d57ad19a23\"/></td></tr><tr ID=\"id_31bdaa9e-0243-4232-9ed2-06fc4d55cb39\"><td align=\"left\" valign=\"top\">Clinical (symptomatic) fractures</td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/></tr><tr ID=\"id_6bdd8717-2021-4b40-9292-521582b7cfd3\"><td align=\"left\" valign=\"top\"> Any clinical (symptomatic) fracture</td><td align=\"center\" valign=\"top\">13.8</td><td align=\"center\" valign=\"top\">18.1</td><td align=\"center\" valign=\"top\">4.3</td><td align=\"center\" valign=\"top\">26<footnote ID=\"id-fd746af6-3f9e-414d-966f-5eb31abbf95f\">p=0.007</footnote> </td></tr><tr ID=\"id_ea66fe8b-2f79-4454-a33c-07a9dafc1908\"><td align=\"left\" valign=\"top\"> &#x2265;1 clinical (symptomatic) vertebral fracture</td><td align=\"center\" valign=\"top\">2.3</td><td align=\"center\" valign=\"top\">5.0</td><td align=\"center\" valign=\"top\">2.7</td><td align=\"center\" valign=\"top\">54<footnote ID=\"id-e5ceb066-65ea-475a-aa1f-384f01aa24ff\">p&lt;0.01</footnote></td></tr><tr ID=\"id_f8f80537-a699-4e5b-a0c1-6f760ce71658\"><td align=\"left\" valign=\"top\">Hip fracture</td><td align=\"center\" valign=\"top\">1.1</td><td align=\"center\" valign=\"top\">2.2</td><td align=\"center\" valign=\"top\">1.1</td><td align=\"center\" valign=\"top\">51<footnote ID=\"id-da034f2a-9536-4018-b513-f8185803bace\">p&lt;0.05</footnote></td></tr><tr ID=\"id_f6fc8fce-af05-4f52-8662-7ea047682af7\"><td align=\"left\" valign=\"top\" styleCode=\"Botrule\">Wrist (forearm) fracture</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">2.2</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">4.1</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">1.9</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">48<footnoteRef IDREF=\"id-da034f2a-9536-4018-b513-f8185803bace\"/></td></tr></tbody></table>","<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"100%\" align=\"center\" valign=\"middle\"/><thead><tr><th>Cumulative Incidence of Hip Fractures in the Three-Year Study of FIT (patients with radiographic vertebral fracture at baseline)</th></tr></thead><tbody><tr><td><renderMultiMedia referencedObject=\"id_1897c942-b9d5-40e2-ac0c-892bf4031250\"/></td></tr></tbody></table>","<table width=\"675.000\" ID=\"id_f167e669-e993-4009-a261-05e219abb774\"><caption ID=\"id_e769c333-19f7-4132-9aa8-3efc8555bd50\">Table 7: Effect of FOSAMAX on Fracture Incidence in Osteoporotic<footnote ID=\"id-719cc014-6e30-4b72-a14f-df41d8fdf284\">Baseline femoral neck BMD at least 2 SD below the mean for young adult women</footnote> Patients in the Four-Year Study of FIT (patients without vertebral fracture at baseline)</caption><col width=\"45%\"/><col width=\"14%\"/><col width=\"14%\"/><col width=\"14%\"/><col width=\"13%\"/><thead><tr ID=\"id_2d9f1254-9151-4596-b4f8-b01b9510b80a\"><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"/><td align=\"center\" valign=\"top\" colspan=\"3\" styleCode=\"Toprule\">Percent of Patients</td><td align=\"left\" valign=\"top\"/></tr><tr ID=\"id_d462d324-399c-4a79-96ea-e376f076ae53\"><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">  FOSAMAX (n=1545)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">  Placebo (n=1521)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">Absolute  Reduction in Fracture Incidence</td><td align=\"center\" valign=\"bottom\" styleCode=\"Botrule\">Relative Reduction in Fracture Risk (%)</td></tr></thead><tbody><tr ID=\"id_3c63e9a4-3ff9-4cb6-8eb6-4ce4a64a0c6f\"><td align=\"left\" valign=\"top\" styleCode=\"Toprule\">Patients with:</td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"/><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"/><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"/><td align=\"center\" valign=\"top\"/></tr><tr ID=\"id_6dc4088c-1021-468d-8028-608ec43cbb69\"><td align=\"left\" valign=\"top\">Vertebral fractures (diagnosed by X-ray)<footnote ID=\"id-dd824089-18f1-4b75-83d4-ea710cae4303\">Number evaluable for vertebral fractures: FOSAMAX, n=1426; placebo, n=1428</footnote></td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/></tr><tr ID=\"id_2c183f90-ee72-4a5a-b868-e9378990feff\"><td align=\"left\" valign=\"top\"> &#x2265;1 new vertebral fracture</td><td align=\"center\" valign=\"top\">2.5</td><td align=\"center\" valign=\"top\">4.8</td><td align=\"center\" valign=\"top\">2.3</td><td align=\"center\" valign=\"top\">48<footnote ID=\"id-7f762425-b63f-4a89-a6b6-f0b9188ef1b8\">p&lt;0.001</footnote></td></tr><tr ID=\"id_211e7d6e-4ebe-4a08-a1f5-dd9c5e138e99\"><td align=\"left\" valign=\"top\"> &#x2265;2 new vertebral fractures</td><td align=\"center\" valign=\"top\">0.1</td><td align=\"center\" valign=\"top\">0.6</td><td align=\"center\" valign=\"top\">0.5</td><td align=\"center\" valign=\"top\">78<footnote ID=\"id-2c6a7ff2-d3f2-4e5b-905e-3c5a804005a1\">p=0.035</footnote></td></tr><tr ID=\"id_a5ddfad4-94f9-41cb-a847-e84404b16dd1\"><td align=\"left\" valign=\"top\">Clinical (symptomatic) fractures</td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/></tr><tr ID=\"id_104a0566-9eb0-4de0-b25a-f598f764f857\"><td align=\"left\" valign=\"top\"> Any clinical (symptomatic) fracture</td><td align=\"center\" valign=\"top\">12.9</td><td align=\"center\" valign=\"top\">16.2</td><td align=\"center\" valign=\"top\">3.3</td><td align=\"center\" valign=\"top\">22<footnote ID=\"id-8c19e2ff-efa9-4d79-b917-3a1af8ce0327\">p=0.01</footnote></td></tr><tr ID=\"id_e3e5c597-05ba-4843-85e7-4be9d6c57be6\"><td align=\"left\" valign=\"top\"> &#x2265;1 clinical (symptomatic) vertebral fracture</td><td align=\"center\" valign=\"top\">1.0</td><td align=\"center\" valign=\"top\">1.6</td><td align=\"center\" valign=\"top\">0.6</td><td align=\"center\" valign=\"top\">41 (NS)<footnote ID=\"id-55063674-a911-451b-b3c4-643ea123d3a4\">Not significant. This study was not powered to detect differences at these sites.</footnote></td></tr><tr ID=\"id_222043eb-ccda-437a-b0f7-0c25940cad01\"><td align=\"left\" valign=\"top\">Hip fracture</td><td align=\"center\" valign=\"top\">1.0</td><td align=\"center\" valign=\"top\">1.4</td><td align=\"center\" valign=\"top\">0.4</td><td align=\"center\" valign=\"top\">29 (NS)<footnoteRef IDREF=\"id-55063674-a911-451b-b3c4-643ea123d3a4\"/></td></tr><tr ID=\"id_1a4357b3-02b5-42a0-b860-013497c60013\"><td align=\"left\" valign=\"top\" styleCode=\"Botrule\">Wrist (forearm) fracture</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">3.9</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">3.8</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">-0.1</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">NS<footnoteRef IDREF=\"id-55063674-a911-451b-b3c4-643ea123d3a4\"/></td></tr></tbody></table>"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The following data are based on findings for the individual components of FOSAMAX PLUS D. Alendronate Sodium Harderian gland (a retro-orbital gland not present in humans) adenomas were increased in high-dose female mice (p=0.003) in a 92-week oral carcinogenicity study at doses of alendronate of 1, 3, and 10 mg/kg/day (males) or 1, 2, and 5 mg/kg/day (females). These doses are equivalent to 0.5 to 4 times the highest recommended clinical daily dose of 10 mg based on surface area, mg/m 2 . The relevance of this finding to humans is unknown. Parafollicular cell (thyroid) adenomas were increased in high-dose male rats (p=0.003) in a 2-year oral carcinogenicity study at doses of 1 and 3.75 mg/kg body weight. These doses are equivalent to 1 and 4 times the 10-mg clinical daily dose based on surface area, mg/m 2 . The relevance of this finding to humans is unknown. Alendronate was not genotoxic in the in vitro microbial mutagenesis assay with and without metabolic activation, in an in vitro mammalian cell mutagenesis assay, in an in vitro alkaline elution assay in rat hepatocytes, and in an in vivo chromosomal aberration assay in mice. In an in vitro chromosomal aberration assay in Chinese hamster ovary cells, however, alendronate gave equivocal results. Alendronate had no effect on fertility (male or female) in rats at oral doses up to 5 mg/kg/day (4 times the 10-mg clinical daily dose based on surface area, mg/m 2 ). Cholecalciferol The carcinogenic potential of cholecalciferol (vitamin D 3 ) has not been studied in rodents. Calcitriol, the hormonal metabolite of cholecalciferol, was not genotoxic in the Ames microbial mutagenesis assay with or without metabolic activation, and in an in vivo micronucleus assay in mice. Ergocalciferol (vitamin D 2 ) at high doses (150,000 to 200,000 international units/kg/day) administered prior to mating resulted in altered estrous cycle and inhibition of pregnancy in rats. The potential effect of cholecalciferol on male fertility is unknown in rats. 13.2 Animal Toxicology and/or Pharmacology The relative inhibitory activities on bone resorption and mineralization of alendronate and etidronate were compared in the Schenk assay, which is based on histological examination of the epiphyses of growing rats. In this assay, the lowest dose of alendronate that interfered with bone mineralization (leading to osteomalacia) was 6000-fold the antiresorptive dose. The corresponding ratio for etidronate was one to one. These data suggest that alendronate administered in therapeutic doses is highly unlikely to induce osteomalacia."],"pharmacodynamics_table":["<table width=\"674.000\" ID=\"id_33d185d5-16ae-490b-a145-ffa76193f162\"><caption ID=\"id_31f24967-464b-44a8-ae59-7f549c9b6412\">Table 4: 25-hydroxyvitamin D Levels after Treatment with FOSAMAX PLUS D (70 mg/2800 international units) or FOSAMAX 70 mg at Week 15<footnote ID=\"id-16b98951-da52-4c81-a132-0bc35447e5cd\">Patients who were vitamin D deficient (25-hydroxyvitamin D less than 9 ng/mL) at baseline were excluded.</footnote></caption><col width=\"26.9%\"/><col width=\"12.3%\"/><col width=\"12.2%\"/><col width=\"12.2%\"/><col width=\"12.2%\"/><col width=\"12.2%\"/><col width=\"12.2%\"/><thead><tr ID=\"id_99d9995a-ab76-4c9f-904f-e72774d23df7\"><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"top\" colspan=\"6\" styleCode=\"Botrule\">Number (%) of Patients</td></tr></thead><tbody><tr ID=\"id_48b266ad-e2a9-4134-970d-694cbcf91606\"><td align=\"left\" valign=\"top\" styleCode=\"Toprule\">25-hydroxyvitamin D Ranges (ng/mL)</td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">&lt;9</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">9-14</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">15-19</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">20-24</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">25-29</content></td><td align=\"center\" valign=\"top\"><content styleCode=\"bold\">30-62</content></td></tr><tr ID=\"id_d6da44a6-5af7-4c9d-8103-ad0ef4676289\"><td align=\"left\" valign=\"top\">FOSAMAX PLUS D (70 mg/2800 international units) (N=357)</td><td align=\"center\" valign=\"top\">4 (1.1)</td><td align=\"center\" valign=\"top\">37 (10.4)</td><td align=\"center\" valign=\"top\">87 (24.4)</td><td align=\"center\" valign=\"top\">84 (23.5)</td><td align=\"center\" valign=\"top\">82 (23.0)</td><td align=\"center\" valign=\"top\">63 (17.7)</td></tr><tr ID=\"id_19f5fbe2-0fd8-4f9c-b884-7b62f6dfb5ff\"><td align=\"left\" valign=\"top\" styleCode=\"Botrule\">FOSAMAX 70 mg (N=351)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">46 (13.1)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">66 (18.8)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">108 (30.8)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">58 (16.5)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">37 (10.5)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">36 (10.3)</td></tr></tbody></table>","<table width=\"669.000\" ID=\"id_c204e164-370f-4a4f-aae9-51c96a1ffe4d\"><caption ID=\"id_2383ab72-da61-430a-b911-d2341fac8ffd\">Table 5: 25-hydroxyvitamin D Levels after Treatment with FOSAMAX PLUS D at Week 39</caption><col width=\"27.1%\"/><col width=\"12.4%\"/><col width=\"11.5%\"/><col width=\"12.3%\"/><col width=\"12.3%\"/><col width=\"12.3%\"/><col width=\"12.3%\"/><thead><tr ID=\"id_bb45522b-f3a4-443a-a8c5-cc7eae0b94e4\"><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"top\" colspan=\"6\" styleCode=\"Botrule\">Number (%) of Patients</td></tr></thead><tbody><tr ID=\"id_2bec0a85-ea19-47d6-8aa9-61c982ad11dd\"><td align=\"left\" valign=\"top\" styleCode=\"Toprule\">25-hydroxyvitamin D Ranges (ng/mL)</td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">&lt;9</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">9-14</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">15-19</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">20-24</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">25-29</content></td><td align=\"center\" valign=\"top\"><content styleCode=\"bold\">30-59</content></td></tr><tr ID=\"id_74e1ded5-80b2-44dc-9493-7b5d684a345d\"><td align=\"left\" valign=\"top\">FOSAMAX PLUS D (Vitamin D<sub>3</sub> 5600 international units group)<footnote ID=\"id-ecf39497-8d2d-4392-afbe-a40030b8b970\">Patients received FOSAMAX 70 mg or FOSAMAX PLUS D (70 mg/2800 international units) for the 15-week base study followed by FOSAMAX PLUS D (70 mg/2800 international units) and 2800 international units additional vitamin D<sub>3</sub> for the 24-week extension study.</footnote> (N=321)</td><td align=\"center\" valign=\"top\">0</td><td align=\"center\" valign=\"top\">10 (3.1)</td><td align=\"center\" valign=\"top\">29 (9.0)</td><td align=\"center\" valign=\"top\">79 (24.6)</td><td align=\"center\" valign=\"top\">87 (27.1)</td><td align=\"center\" valign=\"top\">116 (36.1)</td></tr><tr ID=\"id_6c3f6fc6-1326-4dc1-9631-6822c5090bc5\"><td align=\"left\" valign=\"top\" styleCode=\"Botrule\">FOSAMAX PLUS D (Vitamin D<sub>3</sub> 2800 international units group)<footnote ID=\"id-185f116c-7c8b-42d7-bc9a-cceda7730fa5\">Patients received FOSAMAX 70 mg or FOSAMAX PLUS D (70 mg/2800 international units) for 15-week base study followed by FOSAMAX PLUS D (70 mg/2800 international units) and placebo for the additional vitamin D<sub>3</sub> for 24-week extension study.</footnote> (N=320)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">1 (0.3)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">17 (5.3)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">56 (17.5)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">80 (25.0)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">74 (23.1)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">92 (28.8)</td></tr></tbody></table>"],"adverse_reactions_table":["<table width=\"549.000\" ID=\"id_c051bd44-cd02-4c7a-b2bb-26b99127b377\"><caption ID=\"id_153a66f3-6e83-43b5-8101-0b6973e16edb\">Table 1: Osteoporosis Treatment Studies in Postmenopausal Women Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to 1% of Patients</caption><col width=\"36.1%\"/><col width=\"16.9%\"/><col width=\"16.0%\"/><col width=\"16.0%\"/><col width=\"14.9%\"/><thead><tr ID=\"id_d71e4f2e-7fa4-4f25-8695-f81895ff9f76\"><td align=\"left\" valign=\"top\" styleCode=\"Toprule\"/><td align=\"center\" valign=\"top\" colspan=\"2\" styleCode=\"Botrule Rrule\">United States/Multinational Studies</td><td align=\"center\" valign=\"top\" colspan=\"2\" styleCode=\"Botrule\">Fracture Intervention Trial</td></tr><tr ID=\"id_dbffcb0f-48c3-4550-8465-706d475ff5a1\"><td align=\"left\" valign=\"top\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">FOSAMAX<footnote ID=\"id-23878815-e92d-47c1-b0f2-d9cbaaf36e61\">10 mg/day for three years</footnote> % (n=196)</td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">Placebo % (n=397)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">FOSAMAX<footnote ID=\"id-c73d4154-a99f-40a2-b610-4a069c90f786\">5 mg/day for 2 years and 10 mg/day for either 1 or 2 additional years</footnote> % (n=3236)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">Placebo % (n=3223)</td></tr></thead><tbody><tr ID=\"id_59043c24-d993-4ea4-9a7b-f23cb302c670\"><td align=\"left\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"italics\">Gastrointestinal </content> abdominal pain  nausea  dyspepsia  constipation  diarrhea  flatulence  acid regurgitation  esophageal ulcer  vomiting  dysphagia  abdominal distention  gastritis</td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"> 6.6 3.6 3.6 3.1 3.1 2.6 2.0 1.5 1.0 1.0 1.0 0.5</td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\"> 4.8 4.0 3.5 1.8 1.8 0.5 4.3 0.0 1.5 0.0 0.8 1.3</td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"> 1.5 1.1 1.1 0.0 0.6 0.2 1.1 0.1 0.2 0.1 0.0 0.6</td><td align=\"center\" valign=\"top\"> 1.5 1.5 1.2 0.2 0.3 0.3 0.9 0.1 0.3 0.1 0.0 0.7</td></tr><tr ID=\"id_e8580b31-8d2f-4bb3-8177-a22ed2967116\"><td align=\"left\" valign=\"top\"><content styleCode=\"italics\">Musculoskeletal </content> musculoskeletal (bone, muscle or joint) pain  muscle cramp</td><td align=\"center\" valign=\"top\">  4.1 0.0</td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">  2.5 1.0</td><td align=\"center\" valign=\"top\">  0.4 0.2</td><td align=\"center\" valign=\"top\">  0.3 0.1</td></tr><tr ID=\"id_dc444d82-c204-4719-933e-33d0cea7bd2b\"><td align=\"left\" valign=\"top\"><content styleCode=\"italics\">Nervous System/Psychiatric </content> headache  dizziness</td><td align=\"center\" valign=\"top\"> 2.6 0.0</td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\"> 1.5 1.0</td><td align=\"center\" valign=\"top\"> 0.2 0.0</td><td align=\"center\" valign=\"top\"> 0.2 0.1</td></tr><tr ID=\"id_af7fec09-1727-4c4e-8adb-8decadc73e5a\"><td align=\"left\" valign=\"top\" styleCode=\"Botrule\"><content styleCode=\"italics\">Special Senses </content> taste perversion</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"> 0.5</td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\"> 1.0</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"> 0.1</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"> 0.0</td></tr></tbody></table>","<table width=\"659.000\" ID=\"id_db113edc-3e6b-4336-8b63-9e0d67e02dcf\"><caption ID=\"id_314d13c9-6fba-47ef-b092-80cd2774f633\">Table 2: Osteoporosis Treatment Studies in Postmenopausal Women Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to 1% of Patients</caption><col width=\"49.2%\"/><col width=\"28.4%\"/><col width=\"22.5%\"/><thead><tr ID=\"id_0b6de96b-1f9f-49e8-b73f-15e469d52f34\"><td align=\"left\" valign=\"top\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">Once Weekly FOSAMAX 70 mg  % (n=519)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">FOSAMAX 10 mg/day % (n=370)</td></tr></thead><tbody><tr ID=\"id_cb4ad627-eff5-4489-bdd3-7a35cb119ef3\"><td align=\"left\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"italics\">Gastrointestinal</content>   abdominal pain   dyspepsia   acid regurgitation  nausea  abdominal distention  constipation  flatulence  gastritis  gastric ulcer</td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"> 3.7 2.7 1.9 1.9 1.0 0.8 0.4 0.2 0.0</td><td align=\"center\" valign=\"top\"> 3.0 2.2 2.4 2.4 1.4 1.6 1.6 1.1 1.1</td></tr><tr ID=\"id_9da8753d-bb4d-4313-86fe-f08aaaec0a00\"><td align=\"left\" valign=\"top\" styleCode=\"Botrule\"><content styleCode=\"italics\">Musculoskeletal</content>  musculoskeletal (bone, muscle, joint) pain  muscle cramp</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"> 2.9 0.2</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"> 3.2 1.1</td></tr></tbody></table>","<table width=\"741.000\" ID=\"id_eafbb4e8-4e60-4ef3-908a-3b79180e92c6\"><caption ID=\"id_02f218c8-9007-4c32-b1ac-3d7a32187b28\">Table 3: Osteoporosis Studies in Men Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to 2% of Patients</caption><col width=\"22.3%\"/><col width=\"25.9%\"/><col width=\"13.4%\"/><col width=\"25.9%\"/><col width=\"12.6%\"/><thead><tr ID=\"id_93e0ba54-d6a4-403f-9227-aef4d04051cd\"><td align=\"left\" valign=\"top\" styleCode=\"Toprule\"/><td align=\"center\" valign=\"top\" colspan=\"2\" styleCode=\"Botrule\">Two-year Study</td><td align=\"center\" valign=\"top\" colspan=\"2\" styleCode=\"Botrule\">One-year Study</td></tr><tr ID=\"id_c1505b81-88a3-4ca5-9e70-1b765354b383\"><td align=\"left\" valign=\"top\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"> FOSAMAX 10 mg/day % (n=146)</td><td align=\"center\" valign=\"top\"> Placebo % (n=95)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">Once Weekly FOSAMAX 70 mg % (n=109)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"> Placebo % (n=58)</td></tr></thead><tbody><tr ID=\"id_4470db78-4f95-4bf2-965a-9d309f3da1bb\"><td align=\"left\" valign=\"top\" styleCode=\"Botrule\"><content styleCode=\"italics\">Gastrointestinal </content> acid regurgitation  flatulence  gastroesophageal reflux disease  dyspepsia  diarrhea  abdominal pain  nausea</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"> 4.1 4.1 0.7 3.4 1.4 2.1 2.1</td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\"> 3.2 1.1 3.2 0.0 1.1 1.1 0.0</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"> 0.0 0.0 2.8 2.8 2.8 0.9 0.0</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"> 0.0 0.0 0.0 1.7 0.0 3.4 0.0</td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Medication Guide ). Instruct patients to read the Medication Guide before starting therapy with FOSAMAX PLUS D and to reread it each time the prescription is renewed. Osteoporosis Recommendations, Including Calcium and Vitamin D Supplementation Instruct patients to take supplemental calcium if intake is inadequate. Patients at increased risk for vitamin D insufficiency (e.g., over the age of 70 years, nursing home bound, or chronically ill) should take additional vitamin D if needed [see Dosage and Administration (2.4) ] . Patients with gastrointestinal malabsorption syndromes may require additional vitamin D supplementation. Weight-bearing exercise should be considered along with the modification of certain behavioral factors, such as cigarette smoking and/or excessive alcohol consumption, if these factors exist. Dosing Instructions Instruct patients that the expected benefits of FOSAMAX PLUS D may only be obtained when it is taken with plain water the first thing upon arising for the day at least 30 minutes before the first food, beverage, or medication of the day. Even dosing with orange juice or coffee has been shown to markedly reduce the absorption of alendronate [see Clinical Pharmacology (12.3) ] . Instruct patients not to chew or suck on the tablet because of a potential for oropharyngeal ulceration. Instruct patients to swallow each tablet of FOSAMAX PLUS D with a full glass of water (6-8 ounces) and not to lie down for at least 30 minutes and until after their first food of the day to facilitate delivery to the stomach and thus reduce the potential for esophageal irritation. Instruct patients not to take FOSAMAX PLUS D at bedtime or before arising for the day. Patients should be informed that failure to follow these instructions may increase their risk of esophageal problems. Instruct patients that if they develop symptoms of esophageal disease (such as difficulty or pain upon swallowing, retrosternal pain or new or worsening heartburn) they should stop taking FOSAMAX PLUS D and consult their physician. If patients miss a dose of FOSAMAX PLUS D, instruct patients to take one tablet on the morning after they remember. They should not take two tablets on the same day but should return to taking one tablet once a week, as originally scheduled on their chosen day."],"spl_unclassified_section":["Dist. by: Organon LLC, a subsidiary of ORGANON & Co., Jersey City, NJ 07302, USA For patent information: www.organon.com/our-solutions/patent/ © 2026 Organon group of companies. All rights reserved. uspi-og0217a-t-2602r002","Dist. by: Organon LLC, a subsidiary of ORGANON & Co., Jersey City, NJ 07302, USA For patent information: www.organon.com/our-solutions/patent/ © 2026 Organon group of companies. All rights reserved. Revised: 2/2026 usmg-og0217a-t-2602r002 This Medication Guide has been approved by the U.S. Food and Drug Administration."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION 70 mg alendronate/2800 international units vitamin D 3 or 70 mg alendronate/5600 international units vitamin D 3 tablet once weekly. ( 2.1 , 2.2 ) Instruct patients to: ( 2.3 ) Swallow tablets whole with 6-8 ounces plain water at least 30 minutes before the first food, drink, or medication of the day. Not lie down for at least 30 minutes after taking FOSAMAX PLUS D and until after food. 2.1 Treatment of Osteoporosis in Postmenopausal Women The recommended dosage is one 70 mg alendronate/2800 international units vitamin D 3 or one 70 mg alendronate/5600 international units vitamin D 3 tablet once weekly. For most osteoporotic women, the appropriate dose is FOSAMAX PLUS D (70 mg alendronate/5600 international units vitamin D 3 ) once weekly. 2.2 Treatment to Increase Bone Mass in Men with Osteoporosis The recommended dosage is one 70 mg alendronate/2800 international units vitamin D 3 or one 70 mg alendronate/5600 international units vitamin D 3 tablet once weekly. For most osteoporotic men, the appropriate dose is FOSAMAX PLUS D (70 mg alendronate/5600 international units vitamin D 3 ) once weekly. 2.3 Important Administration Instructions Instruct patients to do the following: Take FOSAMAX PLUS D at least one-half hour before the first food, beverage, or medication of the day with plain water only [see Patient Counseling Information (17) ] . Other beverages (including mineral water), food, and some medications are likely to reduce the absorption of alendronate [see Drug Interactions (7.1) ] . Waiting less than 30 minutes, or taking FOSAMAX PLUS D with food, beverages (other than plain water) or other medications will lessen the effect of alendronate by decreasing its absorption into the body. Take FOSAMAX PLUS D upon arising for the day. To facilitate delivery to the stomach and thus reduce the potential for esophageal irritation, a FOSAMAX PLUS D tablet should be swallowed with a full glass of water (6-8 ounces). Patients should not lie down for at least 30 minutes and until after their first food of the day. FOSAMAX PLUS D should not be taken at bedtime or before arising for the day. Failure to follow these instructions may increase the risk of esophageal adverse experiences [see Warnings and Precautions (5.1) and Patient Counseling Information (17) ] . 2.4 Recommendations for Calcium and Vitamin D Supplementation Instruct patients to take supplemental calcium if dietary intake is inadequate [see Warnings and Precautions (5.2) ] . Patients at increased risk for vitamin D insufficiency (e.g., over the age of 70 years, nursing home bound, or chronically ill) may need additional vitamin D supplementation. Patients with gastrointestinal malabsorption syndromes may require higher doses of vitamin D supplementation and measurement of 25-hydroxyvitamin D should be considered. The recommended intake of vitamin D is 400-800 international units daily. FOSAMAX PLUS D 70 mg/2800 international units and 70 mg/5600 international units are intended to provide seven days' worth of 400 and 800 international units daily vitamin D in a single, once-weekly dose, respectively. 2.5 Administration Instructions for Missed Doses If a once-weekly dose of FOSAMAX PLUS D is missed, instruct patients to take one tablet on the morning after they remember. They should not take two tablets on the same day but should return to taking one tablet once a week, as originally scheduled on their chosen day."],"spl_product_data_elements":["FOSAMAX PLUS D ALENDRONATE SODIUM and CHOLECALCIFEROL ALENDRONATE SODIUM ALENDRONIC ACID CHOLECALCIFEROL CHOLECALCIFEROL BUTYLATED HYDROXYTOLUENE SILICON DIOXIDE CROSCARMELLOSE SODIUM GELATIN, UNSPECIFIED ANHYDROUS LACTOSE MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE SUCROSE STARCH, CORN MEDIUM-CHAIN TRIGLYCERIDES SODIUM ALUMINOSILICATE white to off-white capsule-shaped 710 FOSAMAX PLUS D ALENDRONATE SODIUM and CHOLECALCIFEROL ALENDRONATE SODIUM ALENDRONIC ACID CHOLECALCIFEROL CHOLECALCIFEROL BUTYLATED HYDROXYTOLUENE SILICON DIOXIDE CROSCARMELLOSE SODIUM GELATIN, UNSPECIFIED ANHYDROUS LACTOSE MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE SUCROSE STARCH, CORN MEDIUM-CHAIN TRIGLYCERIDES SODIUM ALUMINOSILICATE white to off-white rectangle-shaped 270"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS 70 mg/2800 international units tablets are white to off-white, modified capsule-shaped tablets with code 710 on one side and an outline of a bone image on the other. 70 mg/5600 international units tablets are white to off-white, modified rectangle-shaped tablets with code 270 on one side and an outline of a bone image on the other. Tablets: 70 mg/2800 international units and 70 mg/5600 international units ( 3 )"],"recent_major_changes_table":["<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"75%\" align=\"left\" valign=\"top\"/><col width=\"25%\" align=\"right\" valign=\"top\"/><tbody><tr><td>Warnings and Precautions, Atypical Fractures Including Femoral Fractures (<linkHtml href=\"#i4i_section_id_b2f11676-5f14-412e-b897-230967e176db\">5.5</linkHtml>) </td><td>2/2026</td></tr></tbody></table>"],"clinical_pharmacology_table":["<table width=\"674.000\" ID=\"id_33d185d5-16ae-490b-a145-ffa76193f162\"><caption ID=\"id_31f24967-464b-44a8-ae59-7f549c9b6412\">Table 4: 25-hydroxyvitamin D Levels after Treatment with FOSAMAX PLUS D (70 mg/2800 international units) or FOSAMAX 70 mg at Week 15<footnote ID=\"id-16b98951-da52-4c81-a132-0bc35447e5cd\">Patients who were vitamin D deficient (25-hydroxyvitamin D less than 9 ng/mL) at baseline were excluded.</footnote></caption><col width=\"26.9%\"/><col width=\"12.3%\"/><col width=\"12.2%\"/><col width=\"12.2%\"/><col width=\"12.2%\"/><col width=\"12.2%\"/><col width=\"12.2%\"/><thead><tr ID=\"id_99d9995a-ab76-4c9f-904f-e72774d23df7\"><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"top\" colspan=\"6\" styleCode=\"Botrule\">Number (%) of Patients</td></tr></thead><tbody><tr ID=\"id_48b266ad-e2a9-4134-970d-694cbcf91606\"><td align=\"left\" valign=\"top\" styleCode=\"Toprule\">25-hydroxyvitamin D Ranges (ng/mL)</td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">&lt;9</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">9-14</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">15-19</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">20-24</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">25-29</content></td><td align=\"center\" valign=\"top\"><content styleCode=\"bold\">30-62</content></td></tr><tr ID=\"id_d6da44a6-5af7-4c9d-8103-ad0ef4676289\"><td align=\"left\" valign=\"top\">FOSAMAX PLUS D (70 mg/2800 international units) (N=357)</td><td align=\"center\" valign=\"top\">4 (1.1)</td><td align=\"center\" valign=\"top\">37 (10.4)</td><td align=\"center\" valign=\"top\">87 (24.4)</td><td align=\"center\" valign=\"top\">84 (23.5)</td><td align=\"center\" valign=\"top\">82 (23.0)</td><td align=\"center\" valign=\"top\">63 (17.7)</td></tr><tr ID=\"id_19f5fbe2-0fd8-4f9c-b884-7b62f6dfb5ff\"><td align=\"left\" valign=\"top\" styleCode=\"Botrule\">FOSAMAX 70 mg (N=351)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">46 (13.1)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">66 (18.8)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">108 (30.8)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">58 (16.5)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">37 (10.5)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">36 (10.3)</td></tr></tbody></table>","<table width=\"669.000\" ID=\"id_c204e164-370f-4a4f-aae9-51c96a1ffe4d\"><caption ID=\"id_2383ab72-da61-430a-b911-d2341fac8ffd\">Table 5: 25-hydroxyvitamin D Levels after Treatment with FOSAMAX PLUS D at Week 39</caption><col width=\"27.1%\"/><col width=\"12.4%\"/><col width=\"11.5%\"/><col width=\"12.3%\"/><col width=\"12.3%\"/><col width=\"12.3%\"/><col width=\"12.3%\"/><thead><tr ID=\"id_bb45522b-f3a4-443a-a8c5-cc7eae0b94e4\"><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"top\" colspan=\"6\" styleCode=\"Botrule\">Number (%) of Patients</td></tr></thead><tbody><tr ID=\"id_2bec0a85-ea19-47d6-8aa9-61c982ad11dd\"><td align=\"left\" valign=\"top\" styleCode=\"Toprule\">25-hydroxyvitamin D Ranges (ng/mL)</td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">&lt;9</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">9-14</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">15-19</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">20-24</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">25-29</content></td><td align=\"center\" valign=\"top\"><content styleCode=\"bold\">30-59</content></td></tr><tr ID=\"id_74e1ded5-80b2-44dc-9493-7b5d684a345d\"><td align=\"left\" valign=\"top\">FOSAMAX PLUS D (Vitamin D<sub>3</sub> 5600 international units group)<footnote ID=\"id-ecf39497-8d2d-4392-afbe-a40030b8b970\">Patients received FOSAMAX 70 mg or FOSAMAX PLUS D (70 mg/2800 international units) for the 15-week base study followed by FOSAMAX PLUS D (70 mg/2800 international units) and 2800 international units additional vitamin D<sub>3</sub> for the 24-week extension study.</footnote> (N=321)</td><td align=\"center\" valign=\"top\">0</td><td align=\"center\" valign=\"top\">10 (3.1)</td><td align=\"center\" valign=\"top\">29 (9.0)</td><td align=\"center\" valign=\"top\">79 (24.6)</td><td align=\"center\" valign=\"top\">87 (27.1)</td><td align=\"center\" valign=\"top\">116 (36.1)</td></tr><tr ID=\"id_6c3f6fc6-1326-4dc1-9631-6822c5090bc5\"><td align=\"left\" valign=\"top\" styleCode=\"Botrule\">FOSAMAX PLUS D (Vitamin D<sub>3</sub> 2800 international units group)<footnote ID=\"id-185f116c-7c8b-42d7-bc9a-cceda7730fa5\">Patients received FOSAMAX 70 mg or FOSAMAX PLUS D (70 mg/2800 international units) for 15-week base study followed by FOSAMAX PLUS D (70 mg/2800 international units) and placebo for the additional vitamin D<sub>3</sub> for 24-week extension study.</footnote> (N=320)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">1 (0.3)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">17 (5.3)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">56 (17.5)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">80 (25.0)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">74 (23.1)</td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">92 (28.8)</td></tr></tbody></table>"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Pregnancy: Discontinue when pregnancy is recognized. ( 8.1 ) FOSAMAX PLUS D is not indicated for use in pediatric patients. ( 8.4 ) FOSAMAX PLUS D is not recommended in patients with severe renal impairment (creatinine clearance less than 35 mL/min). ( 5.6 , 8.6 ) 8.1 Pregnancy Risk Summary Available data on the use of FOSAMAX plus vitamin D use in pregnant women are insufficient to inform a drug-associated risk of adverse maternal or fetal outcomes. Discontinue FOSAMAX PLUS D when pregnancy is recognized. Alendronate Sodium In animal reproduction studies, daily oral administration of alendronate to rats from before mating through the end of gestation or lactation showed decreased postimplantation survival and decreased pup body weight gain starting at doses equivalent to less than half of the highest recommended 40 mg clinical daily dose (based on body surface area, mg/m 2 ). Oral administration of alendronate to rats during organogenesis resulted in reduced fetal ossification starting at doses 3 times the 40 mg clinical daily dose. No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at doses equivalent to approximately 10 times the 40 mg clinical daily dose. Delayed or failed delivery of offspring, protracted parturition, and late pregnancy maternal and fetal deaths due to maternal hypocalcemia occurred in rats at oral doses as low as one tenth the 40 mg clinical daily dose (see Data ) . Bisphosphonates are incorporated into the bone matrix, from which they are gradually released over a period of years. The amount of bisphosphonate incorporated into adult bone and available for release into the systemic circulation is directly related to the dose and duration of bisphosphonate use. Consequently, based on the mechanism of action of bisphosphonates, there is a potential risk of fetal harm, predominantly skeletal, if a woman becomes pregnant after completing a course of bisphosphonate therapy. The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of administration (intravenous versus oral) on the risk has not been studied. Cholecalciferol No data are available for cholecalciferol (vitamin D 3 ) in animals. However, administration of high doses of vitamin D 2 to pregnant rabbits resulted in abortions and an increased incidence of fetal aortic stenosis. Administration of high doses of vitamin D 2 to pregnant rats resulted in neonatal death, decreased fetal weight, and impaired osteogenesis of long bones postnatally. (See Data .) The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Alendronate Sodium Reproduction studies in rats dosed orally from before mating to the end of gestation or lactation showed decreased postimplantation survival starting at 2 mg/kg/day and decreased body weight gain starting at 1 mg/kg/day, doses equivalent to less than half the 40 mg clinical daily dose based on body surface area, mg/m 2 . Incidence of incomplete fetal ossification in vertebral, skull, and sternebral bones were increased in rats dosed orally during organogenesis starting at 10 mg/kg/day (approximately 3 times the 40 mg clinical daily dose). No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at up to 35 mg/kg/day (equivalent to approximately 10 times the 40 mg clinical daily dose). Both total and ionized calcium decreased in pregnant rats dosed orally with 15 mg/kg/day alendronate (approximately 4 times the 40 mg clinical daily dose) resulting in delays and failures of delivery. Protracted parturition due to maternal hypocalcemia was observed when rats were treated from before mating through gestation starting at 0.5 mg/kg/day (approximately one tenth the 40 mg clinical daily dose). Maternotoxicity (late pregnancy deaths) also occurred in female rats treated orally with 15 mg/kg/day (approximately 4 times the 40 mg clinical daily dose) for varying gestational time periods. These maternal deaths were lessened but not eliminated by cessation of treatment. Calcium supplementation in the drinking water or by subcutaneous minipump to rats dosed orally with 15 mg/kg/day alendronate could not ameliorate the hypocalcemia or prevent the dystocia-related maternal and neonatal deaths. However, intravenous calcium supplementation prevented maternal, but not neonatal deaths. Cholecalciferol Administration of high doses (greater than or equal to 10,000 international units/every other day during pregnancy) of ergocalciferol (vitamin D 2 ) to pregnant rabbits resulted in abortions and an increased incidence of fetal aortic stenosis. Administration of vitamin D 2 (40,000 international units/day) to pregnant rats from gestation day 10 to 21 (organogenesis) resulted in neonatal death, decreased fetal weight, and impaired osteogenesis of long bones postnatally. 8.2 Lactation Risk Summary Cholecalciferol and some of its active metabolites pass into breast milk. It is not known whether alendronate is present in human breast milk, affects human milk production, or has effects on the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for FOSAMAX PLUS D and any potential adverse effects on the breastfed child from FOSAMAX PLUS D or from the underlying maternal condition. 8.4 Pediatric Use FOSAMAX PLUS D is not indicated for use in pediatric patients. The safety and efficacy of alendronate were examined in a randomized, double-blind, placebo-controlled two-year study of 139 pediatric patients, aged 4-18 years, with severe osteogenesis imperfecta (OI). One-hundred-and-nine patients were randomized to 5 mg alendronate daily (weight less than 40 kg) or 10 mg alendronate daily (weight greater than or equal to 40 kg) and 30 patients to placebo. The mean baseline lumbar spine BMD Z-score of the patients was -4.5. The mean change in lumbar spine BMD Z-score from baseline to Month 24 was 1.3 in the alendronate-treated patients and 0.1 in the placebo-treated patients. Treatment with alendronate did not reduce the risk of fracture. Sixteen percent of the alendronate patients who sustained a radiologically-confirmed fracture by Month 12 of the study had delayed fracture healing (callus remodeling) or fracture non-union when assessed radiographically at Month 24 compared with 9% of the placebo-treated patients. In alendronate-treated patients, bone histomorphometry data obtained at Month 24 demonstrated decreased bone turnover and delayed mineralization time; however, there were no mineralization defects. There were no statistically significant differences between the alendronate and placebo groups in reduction of bone pain. The oral bioavailability of alendronate in children was similar to that observed in adults. 8.5 Geriatric Use Of the patients receiving FOSAMAX in the Fracture Intervention Trial (FIT), 71% (n=2302) were greater than or equal to 65 years of age and 17% (n=550) were greater than or equal to 75 years of age. Of the patients receiving FOSAMAX in the United States and Multinational osteoporosis treatment studies in women, and osteoporosis studies in men [see Clinical Studies ( 14.1 , 14.2 )] , 45% and 54%, respectively, were 65 years of age or over. No overall differences in efficacy or safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Dietary requirements of vitamin D 3 are increased in the elderly. 8.6 Renal Impairment FOSAMAX PLUS D is not recommended for patients with creatinine clearance less than 35 mL/min . No dosage adjustment is necessary in patients with creatinine clearance values between 35-60 mL/min [see Clinical Pharmacology (12.3) ] . 8.7 Hepatic Impairment Alendronate Sodium As there is evidence that alendronate is not metabolized or excreted in the bile, no studies were conducted in patients with hepatic impairment. No dosage adjustment is necessary [see Clinical Pharmacology (12.3) ] . Cholecalciferol Vitamin D 3 may not be adequately absorbed in patients who have malabsorption due to inadequate bile production."],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology The relative inhibitory activities on bone resorption and mineralization of alendronate and etidronate were compared in the Schenk assay, which is based on histological examination of the epiphyses of growing rats. In this assay, the lowest dose of alendronate that interfered with bone mineralization (leading to osteomalacia) was 6000-fold the antiresorptive dose. The corresponding ratio for etidronate was one to one. These data suggest that alendronate administered in therapeutic doses is highly unlikely to induce osteomalacia."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 70 mg/2800 IU Tablet Blister Pack FOSAMAX ® PLUS D (alendronate sodium/ cholecalciferol) tablets 70 mg 2800 IU Dispense the enclosed Medication Guide to each patient. Each tablet contains 91.37 mg alendronate sodium (70 mg free acid equivalent) and 70 mcg cholecalciferol equivalent to 2800 IU vitamin D. 710 4 Tablets Rx only USUAL ADULT DOSAGE: ONE 70 mg/2800 IU TABLET ONCE WEEKLY See accompanying circular for dosage information. Manuf. for: Organon LLC, a subsidiary of ORGANON & Co., Jersey City, NJ 07302, USA By: Rovi Pharma Industrial Services, S.A. 28805 Alcalá de Henares Madrid, Spain Made in Spain PRINCIPAL DISPLAY PANEL - 70 mg/2800 IU Tablet Blister Pack","PRINCIPAL DISPLAY PANEL - 70 mg/5600 IU Tablet Blister Pack FOSAMAX ® PLUS D (alendronate sodium/ cholecalciferol) tablets 70 mg 5600 IU Dispense the enclosed Medication Guide to each patient. Each tablet contains 91.37 mg alendronate sodium (70 mg free acid equivalent) and 140 mcg cholecalciferol equivalent to 5600 IU vitamin D. 270 4 Tablets Rx only USUAL ADULT DOSAGE: ONE 70 mg/5600 IU TABLET ONCE WEEKLY See accompanying circular for dosage information. Manuf. for: Organon LLC, a subsidiary of ORGANON & Co., Jersey City, NJ 07302, USA By: Rovi Pharma Industrial Services, S.A. 28805 Alcalá de Henares Madrid, Spain Made in Spain PRINCIPAL DISPLAY PANEL - 70 mg/5600 IU Tablet Blister Pack"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The following data are based on findings for the individual components of FOSAMAX PLUS D. Alendronate Sodium Harderian gland (a retro-orbital gland not present in humans) adenomas were increased in high-dose female mice (p=0.003) in a 92-week oral carcinogenicity study at doses of alendronate of 1, 3, and 10 mg/kg/day (males) or 1, 2, and 5 mg/kg/day (females). These doses are equivalent to 0.5 to 4 times the highest recommended clinical daily dose of 10 mg based on surface area, mg/m 2 . The relevance of this finding to humans is unknown. Parafollicular cell (thyroid) adenomas were increased in high-dose male rats (p=0.003) in a 2-year oral carcinogenicity study at doses of 1 and 3.75 mg/kg body weight. These doses are equivalent to 1 and 4 times the 10-mg clinical daily dose based on surface area, mg/m 2 . The relevance of this finding to humans is unknown. Alendronate was not genotoxic in the in vitro microbial mutagenesis assay with and without metabolic activation, in an in vitro mammalian cell mutagenesis assay, in an in vitro alkaline elution assay in rat hepatocytes, and in an in vivo chromosomal aberration assay in mice. In an in vitro chromosomal aberration assay in Chinese hamster ovary cells, however, alendronate gave equivocal results. Alendronate had no effect on fertility (male or female) in rats at oral doses up to 5 mg/kg/day (4 times the 10-mg clinical daily dose based on surface area, mg/m 2 ). Cholecalciferol The carcinogenic potential of cholecalciferol (vitamin D 3 ) has not been studied in rodents. Calcitriol, the hormonal metabolite of cholecalciferol, was not genotoxic in the Ames microbial mutagenesis assay with or without metabolic activation, and in an in vivo micronucleus assay in mice. Ergocalciferol (vitamin D 2 ) at high doses (150,000 to 200,000 international units/kg/day) administered prior to mating resulted in altered estrous cycle and inhibition of pregnancy in rats. The potential effect of cholecalciferol on male fertility is unknown in rats."]},"tags":[{"label":"Bisphosphonate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Farnesyl pyrophosphate synthase","category":"target"},{"label":"FDPS","category":"gene"},{"label":"FNTB","category":"gene"},{"label":"M05BA04","category":"atc"},{"label":"Oral","category":"route"},{"label":"Solution","category":"form"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Glucocorticoid Induced Osteoporosis","category":"indication"},{"label":"Hypogonadal Osteoporosis in Males","category":"indication"},{"label":"Osteitis deformans","category":"indication"},{"label":"Postmenopausal osteoporosis","category":"indication"},{"label":"Prevention of Glucocorticoid-Induced Osteoporosis","category":"indication"},{"label":"Merck And Co Inc","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Bone Density Conservation Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":8586.23,"date":"","count":4477,"signal":"Femur fracture","source":"DrugCentral FAERS","actionTaken":"Reported 4,477 times (LLR=8586)"},{"llr":4362.26,"date":"","count":5363,"signal":"Pemphigus","source":"DrugCentral FAERS","actionTaken":"Reported 5,363 times (LLR=4362)"},{"llr":4025.855,"date":"","count":5486,"signal":"Systemic lupus erythematosus","source":"DrugCentral FAERS","actionTaken":"Reported 5,486 times (LLR=4026)"},{"llr":3859.32,"date":"","count":1269,"signal":"Low turnover osteopathy","source":"DrugCentral FAERS","actionTaken":"Reported 1,269 times (LLR=3859)"},{"llr":3734.914,"date":"","count":4899,"signal":"Glossodynia","source":"DrugCentral FAERS","actionTaken":"Reported 4,899 times (LLR=3735)"},{"llr":3272.437,"date":"","count":2212,"signal":"Osteonecrosis","source":"DrugCentral FAERS","actionTaken":"Reported 2,212 times (LLR=3272)"},{"llr":2957,"date":"","count":2318,"signal":"Osteonecrosis of jaw","source":"DrugCentral FAERS","actionTaken":"Reported 2,318 times (LLR=2957)"},{"llr":2896.673,"date":"","count":4089,"signal":"Hand deformity","source":"DrugCentral FAERS","actionTaken":"Reported 4,089 times (LLR=2897)"},{"llr":2636.634,"date":"","count":6001,"signal":"Alopecia","source":"DrugCentral FAERS","actionTaken":"Reported 6,001 times (LLR=2637)"},{"llr":2605.359,"date":"","count":4964,"signal":"Arthropathy","source":"DrugCentral FAERS","actionTaken":"Reported 4,964 times (LLR=2605)"},{"llr":2601.926,"date":"","count":790,"signal":"Intramedullary rod insertion","source":"DrugCentral FAERS","actionTaken":"Reported 790 times (LLR=2602)"},{"llr":2531.426,"date":"","count":6055,"signal":"Abdominal discomfort","source":"DrugCentral FAERS","actionTaken":"Reported 6,055 times (LLR=2531)"},{"llr":2402.88,"date":"","count":3893,"signal":"Wound","source":"DrugCentral FAERS","actionTaken":"Reported 3,893 times (LLR=2403)"},{"llr":1872.616,"date":"","count":2794,"signal":"Anti-cyclic citrullinated peptide antibody positive","source":"DrugCentral FAERS","actionTaken":"Reported 2,794 times (LLR=1873)"},{"llr":1865.15,"date":"","count":923,"signal":"Stress fracture","source":"DrugCentral FAERS","actionTaken":"Reported 923 times (LLR=1865)"}],"commonSideEffects":[{"effect":"Abdominal distention","drugRate":"4.3%","severity":"mild","_validated":true},{"effect":"Abdominal pain","drugRate":"4.1%","severity":"mild","_validated":true},{"effect":"Musculoskeletal (bone, muscle, joint) pain","drugRate":"4.1%","severity":"mild","_validated":true},{"effect":"Nausea","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Dyspepsia","drugRate":"3.7%","severity":"mild","_validated":true},{"effect":"Acid regurgitation","drugRate":"3.7%","severity":"mild","_validated":true},{"effect":"Constipation","drugRate":"3.2%","severity":"mild","_validated":true},{"effect":"Diarrhea","drugRate":"3.2%","severity":"mild","_validated":true},{"effect":"Flatulence","drugRate":"3.2%","severity":"mild","_validated":true},{"effect":"Gastritis","drugRate":"3.2%","severity":"mild","_validated":true},{"effect":"Gastric ulcer","drugRate":"3.2%","severity":"serious","_validated":true},{"effect":"Muscle cramp","drugRate":"2.9%","severity":"mild","_validated":true},{"effect":"Headache","drugRate":"2.6%","severity":"mild","_validated":true},{"effect":"Dizziness","drugRate":"2.5%","severity":"mild","_validated":true},{"effect":"Gastroesophageal reflux disease","drugRate":"2.1%","severity":"mild","_validated":true},{"effect":"Rash","drugRate":"reported","severity":"unknown"},{"effect":"Erythema","drugRate":"reported","severity":"unknown"}],"contraindications":["Achalasia of esophagus","Acute nephropathy","Acute peptic ulcer","Arteriosclerosis obliterans","Aseptic necrosis of bone of jaw","Atrial fibrillation","Bed-ridden","Duodenitis","Dysphagia","Esophageal Obstruction","Esophageal dysmotility","Esophagitis","Fracture of femur","Gastritis","High Grade Dysplasia associated with Barrett's Esophagus","Hypercalcemia","Hyperphosphatemia","Hypervitaminosis D","Hypocalcemia","Joint pain","Kidney disease","Kidney stone","Sarcoidosis","Stricture of esophagus","Ulcer of esophagus"],"specialPopulations":{"Pregnancy":"Teratogenic Effects. Pregnancy category C. Reproduction studies in rats showed decreased postimplantation survival at mg/kg/day and decreased body weight gain in normal pups at mg/kg/day. Sites of incomplete fetal ossification were statistically significantly increased in rats beginning at 10 mg/kg/day in vertebral (cervical, thoracic, and lumbar), skull, and sternebral bones. The above doses ranged from 0.26 times (1 mg/kg) to 2.6 times (10 mg/kg) maximum recommended daily dose of 40","Geriatric use":"Of the patients receiving alendronate sodium in the Fracture Intervention Trial (FIT), 71% (n=2302) were >=65 years of age and 17% (n=550) were >=75 years of age. Of the patients receiving alendronate sodium in the United States and Multinational osteoporosis treatment studies in women, osteoporosis studies in men, glucocorticoid-induced osteoporosis studies, and Pagets disease studies (see CLINICAL PHARMACOLOGY, Clinical Studies), 45%, 54%, 37%, and 70%, respectively, were 65 yea","Paediatric use":"The efficacy and safety of alendronate sodium were examined in randomized, double-blind, placebo-controlled two-year study of 139 pediatric patients, aged to 18 years, with severe osteogenesis imperfecta. One-hundred-and-nine patients were randomized to mg alendronate sodium daily (weight 40 kg) or 10 mg alendronate sodium daily (weight >= 40 kg) and 30 patients to placebo. The mean baseline lumbar spine BMD Z-score of the patients was -4.5. The mean change in lumbar spine BMD Z-s","Renal impairment":"No dosage adjustment is necessary for patients with mild-to-moderate renal insufficiency (creatinine clearance ...). Although no clinical information is available, it is likely that, as in animals, elimination of alendronate via the kidney will be reduced in patients with impaired renal function. Therefore, somewhat greater accumulation of alendronate in bone might be expected in patients with impaired renal function."}},"trials":[],"aliases":[],"company":"Merck And Co Inc","patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2031-12-05","territory":"US","patentNumber":"9592195"},{"source":"FDA Orange Book via DrugCentral","expires":"2023-08-11","territory":"US","patentNumber":"7488496"},{"source":"FDA Orange Book via DrugCentral","expires":"2023-03-06","territory":"US","patentNumber":"7964212"}],"pricing":[],"_fixedAt":"2026-03-30T16:30:24.156375","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ALENDRONIC ACID","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:04:41.102759+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T02:04:41.102318+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Alendronic Acid","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T02:04:50.646651+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:04:48.610304+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALENDRONIC ACID","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:04:49.262393+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:04:38.685624+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:04:38.685687+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:04:38.685709+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL870/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:04:50.533557+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA021762","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:04:38.685720+00:00"}},"allNames":"fosamax","offLabel":[],"synonyms":["alendronate monosodium salt trihydrate","alendronate sodium trihydrate","alendronate sodium hydrate","alendronate","alendronic acid","alendronate sodium","aminohydroxybutane bisphosphonate","MK-217"],"timeline":[{"date":"1995-09-29","type":"positive","source":"DrugCentral","milestone":"FDA approval (Merck And Co Inc)"}],"brandName":"Fosamax","ecosystem":[{"indication":"Glucocorticoid Induced Osteoporosis","otherDrugs":[{"name":"colecalciferol","slug":"colecalciferol","company":"Sandoz"},{"name":"ergocalciferol","slug":"ergocalciferol","company":"Sanofi Aventis Us"},{"name":"risedronic acid","slug":"risedronic-acid","company":"Warner Chilcott Llc"},{"name":"teriparatide","slug":"teriparatide","company":"Lilly"}],"globalPrevalence":200000000},{"indication":"Hypogonadal Osteoporosis in Males","otherDrugs":[{"name":"colecalciferol","slug":"colecalciferol","company":"Sandoz"},{"name":"ergocalciferol","slug":"ergocalciferol","company":"Sanofi Aventis Us"},{"name":"teriparatide","slug":"teriparatide","company":"Lilly"},{"name":"zoledronic acid","slug":"zoledronic-acid","company":"Novartis"}],"globalPrevalence":200000000},{"indication":"Osteitis deformans","otherDrugs":[{"name":"calcitonin (salmon synthetic)","slug":"calcitonin-(salmon-synthetic)","company":"Sanofi Aventis Us"},{"name":"etidronic acid","slug":"etidronic-acid","company":"Procter And Gamble"},{"name":"pamidronic acid","slug":"pamidronic-acid","company":""},{"name":"risedronic acid","slug":"risedronic-acid","company":"Warner Chilcott Llc"}],"globalPrevalence":null},{"indication":"Postmenopausal osteoporosis","otherDrugs":[{"name":"bazedoxifene","slug":"bazedoxifene","company":"Wyeth Pharms Pfizer"},{"name":"calcitonin (salmon synthetic)","slug":"calcitonin-(salmon-synthetic)","company":"Sanofi Aventis Us"},{"name":"calcium citrate","slug":"calcium-citrate","company":""},{"name":"calcium phosphate","slug":"calcium-phosphate","company":""}],"globalPrevalence":200000000},{"indication":"Prevention of Glucocorticoid-Induced Osteoporosis","otherDrugs":[{"name":"risedronic acid","slug":"risedronic-acid","company":"Warner Chilcott Llc"},{"name":"zoledronic acid","slug":"zoledronic-acid","company":"Novartis"}],"globalPrevalence":200000000}],"mechanism":{"target":"Farnesyl pyrophosphate synthase","novelty":"Follow-on","targets":[{"gene":"FDPS","source":"DrugCentral","target":"Farnesyl pyrophosphate synthase","protein":"Farnesyl pyrophosphate synthase"},{"gene":"FNTB","source":"DrugCentral","target":"Protein farnesyltransferase subunit beta","protein":"Protein farnesyltransferase subunit beta"}],"modality":"Small Molecule","drugClass":"Vitamin D [EPC]","explanation":"Mechanism of Action. Animal studies have indicated the following mode of action. At the cellular level, alendronate shows preferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active resorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [3H]alendronate in bone showed about 10-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones examined and 49 days after [3H]alendronate administration in rats and mice, respectively, showed that normal bone was formed on top of the alendronate, which was incorporated inside the matrix. While incorporated in bone matrix, alendronate is not pharmacologically active. Thus, alendronate must be continuously administered to suppress osteoclasts on newly formed resorption surfaces.","oneSentence":"Fosamax works by inhibiting bone resorption, allowing bone density to increase.","technicalDetail":"Fosamax (Alendronic Acid) acts as a potent inhibitor of farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway, which is essential for bone resorption. By inhibiting this enzyme, Fosamax reduces the production of osteoclasts, leading to decreased bone resorption and increased bone density.","_target_confidence":0.5},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Alendronic_acid","title":"Alendronic acid","extract":"Alendronic acid or Alendronate, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone, which works by decreasing the activity of osteoclasts, the cells that break down bone. It is taken by mouth as the neutral sodium salt, alendronate sodium, but is absorbed as the active free drug alendronic acid. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes."},"commercial":{"launchDate":"1995","_launchSource":"DrugCentral (FDA 1995-09-29, MERCK AND CO INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/112","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ALENDRONIC%20ACID","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALENDRONIC ACID","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Alendronic_acid","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T08:35:57.127237","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:04:56.407280+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"etidronic acid","drugSlug":"etidronic-acid","fdaApproval":"1977-09-01","relationship":"same-class"},{"drugName":"pamidronic acid","drugSlug":"pamidronic-acid","fdaApproval":"1991-10-31","relationship":"same-class"},{"drugName":"tiludronic acid","drugSlug":"tiludronic-acid","fdaApproval":"1997-03-07","relationship":"same-class"},{"drugName":"ibandronic acid","drugSlug":"ibandronic-acid","fdaApproval":"2003-05-16","relationship":"same-class"},{"drugName":"risedronic acid","drugSlug":"risedronic-acid","fdaApproval":"1998-03-27","relationship":"same-class"},{"drugName":"zoledronic acid","drugSlug":"zoledronic-acid","fdaApproval":"2001-08-20","patentExpiry":"Feb 5, 2028","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"alendronic acid","indications":{"approved":[{"name":"Glucocorticoid Induced Osteoporosis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":{"men and women":"receiving glucocorticoids in daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density","calcium and vitamin D":"should receive adequate amounts"},"usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"},{"name":"Hypogonadal Osteoporosis in Males","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":{"men":"with osteoporosis"},"usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"},{"name":"Osteitis deformans","source":"DrugCentral","snomedId":2089002,"regulator":"FDA","eligibility":{"men and women":"having alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease"}},{"name":"Postmenopausal osteoporosis","source":"DrugCentral","snomedId":102447009,"regulator":"FDA","eligibility":{"risk factors":["early menopause","moderately low bone mass (at least standard deviation below the mean for healthy young adult women)","thin body build","Caucasian or Asian race","family history of osteoporosis"],"postmenopausal women":"at risk of developing osteoporosis, with risk factors including"},"usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"},{"name":"Prevention of Glucocorticoid-Induced Osteoporosis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":{"men and women":"receiving glucocorticoids in daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density"},"usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"}],"offLabel":[{"name":"Complex regional pain syndrome","source":"DrugCentral","drugName":"ALENDRONIC ACID","evidenceCount":0,"evidenceLevel":"emerging"}],"pipeline":[]},"_fixedFields":["pubmed(190)"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"etidronic-acid","brandName":"etidronic acid","genericName":"etidronic acid","approvalYear":"1977","relationship":"same-class"},{"drugId":"pamidronic-acid","brandName":"pamidronic acid","genericName":"pamidronic acid","approvalYear":"1991","relationship":"same-class"},{"drugId":"tiludronic-acid","brandName":"tiludronic acid","genericName":"tiludronic acid","approvalYear":"1997","relationship":"same-class"},{"drugId":"ibandronic-acid","brandName":"ibandronic acid","genericName":"ibandronic acid","approvalYear":"2003","relationship":"same-class"},{"drugId":"risedronic-acid","brandName":"risedronic acid","genericName":"risedronic acid","approvalYear":"1998","relationship":"same-class"},{"drugId":"zoledronic-acid","brandName":"zoledronic acid","genericName":"zoledronic acid","approvalYear":"2001","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07471880","phase":"PHASE2","title":"A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head","status":"ACTIVE_NOT_RECRUITING","sponsor":"ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.","startDate":"2024-12-24","conditions":["Osteonecrosis","Osteonecrosis of the Femoral Head"],"enrollment":161,"completionDate":"2027-02-28"},{"nctId":"NCT06973109","phase":"PHASE2","title":"Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes","status":"NOT_YET_RECRUITING","sponsor":"Nitin Agarwal","startDate":"2026-03-20","conditions":["Osteoporosis, Post-menopausal"],"enrollment":36,"completionDate":"2027-06"},{"nctId":"NCT07435051","phase":"PHASE3","title":"Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-05-01","conditions":["Osteomyelitis (Refractory)"],"enrollment":280,"completionDate":"2030-12-31"},{"nctId":"NCT06016634","phase":"PHASE2","title":"Alendronate for Osteonecrosis in Adults With Sickle Cell Disease","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2026-02-09","conditions":["Sickle Cell Disease","Sickle Cell Anemia","Osteonecrosis","Ischemic Necrosis","Avascular Necrosis"],"enrollment":30,"completionDate":"2027-12-31"},{"nctId":"NCT05764733","phase":"PHASE4","title":"Bone, Exercise, Alendronate, and Caloric Restriction","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2023-06-08","conditions":["Bone Loss"],"enrollment":900,"completionDate":"2027-09"},{"nctId":"NCT07245381","phase":"PHASE1,PHASE2","title":"Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation","status":"NOT_YET_RECRUITING","sponsor":"Dr. Itay GoorAryeh","startDate":"2025-12","conditions":["Cervix Cancer"],"enrollment":65,"completionDate":"2026-09"},{"nctId":"NCT07242612","phase":"NA","title":"Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis","status":"RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2025-10-01","conditions":["Osteoporosis","Osteoporosis, Postmenopausal"],"enrollment":40,"completionDate":"2026-04-15"},{"nctId":"NCT05091099","phase":"PHASE4","title":"The Optimal Sequential Therapy After Long Term Denosumab Treatment","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2022-01-10","conditions":["Osteoporosis"],"enrollment":44,"completionDate":"2025-11-14"},{"nctId":"NCT03292146","phase":"PHASE3","title":"Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-10-25","conditions":["Bone Density","Bone Loss","Anorexia Nervosa","Eating Disorder","Atypical Anorexia Nervosa"],"enrollment":30,"completionDate":"2021-07-22"},{"nctId":"NCT07216794","phase":"PHASE2","title":"Small Trial of Alendronate Impact on the Reservoir of HIV","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-01-17","conditions":["HIV"],"enrollment":30,"completionDate":"2027-05-21"},{"nctId":"NCT04708886","phase":"PHASE2","title":"Romosozumab in Women With Chronic SCI","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2021-03-01","conditions":["Osteoporosis","Bone Loss","Osteopenia, Osteoporosis","Spinal Cord Injuries","Chronic Spinal Paralysis"],"enrollment":12,"completionDate":"2024-06-10"},{"nctId":"NCT01648686","phase":"NA","title":"Bone Healing After Dental Extraction in Postmenopausal Osteoporotic Women Treated With Alendronate Per os Weekly","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-09-19","conditions":["Alveolar Bone Healing After Dental Extraction"],"enrollment":66,"completionDate":"2015-11-05"},{"nctId":"NCT05493761","phase":"PHASE4","title":"Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aristotle University Of Thessaloniki","startDate":"2022-12-23","conditions":["Nonalcoholic Fatty Liver","Osteoporosis, Postmenopausal"],"enrollment":72,"completionDate":"2026-09"},{"nctId":"NCT07028320","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2021-12-03","conditions":["Postmenopausal Women With Osteoporosis"],"enrollment":493,"completionDate":"2024-05-20"},{"nctId":"NCT05575167","phase":"","title":"Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)","status":"RECRUITING","sponsor":"424 General Military Hospital","startDate":"2023-11-28","conditions":["Osteoporosis, Postmenopausal"],"enrollment":125,"completionDate":"2027-11"},{"nctId":"NCT05151484","phase":"PHASE4","title":"Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover","status":"RECRUITING","sponsor":"Madhumathi Rao","startDate":"2022-03-21","conditions":["Age-Related Osteoporosis"],"enrollment":60,"completionDate":"2026-08-31"},{"nctId":"NCT06264609","phase":"PHASE4","title":"Precision Medicine Approach for Osteoporosis - Follow Up Study","status":"ENROLLING_BY_INVITATION","sponsor":"Paul F Netzel","startDate":"2024-02-01","conditions":["Osteoporosis"],"enrollment":40,"completionDate":"2029-12-31"},{"nctId":"NCT06864130","phase":"PHASE4","title":"A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2025-02-21","conditions":["Osteoporosis in Post-menopausal Women"],"enrollment":1400,"completionDate":"2029-09-15"},{"nctId":"NCT06856369","phase":"PHASE4","title":"Clinical Efficacy of 1% Metformin and Alendronate Gel in Adjunct to Fibrin in Chronic Periodontitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bahria University","startDate":"2025-01-22","conditions":["Alveolar Bone Loss Associated Chronic Periodontitis"],"enrollment":120,"completionDate":"2027-09-30"},{"nctId":"NCT01631214","phase":"PHASE3","title":"Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-05-04","conditions":["Postmenopausal Women With Osteoporosis"],"enrollment":4093,"completionDate":"2017-06-29"},{"nctId":"NCT06772792","phase":"PHASE1","title":"A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-23","conditions":["Healthy"],"enrollment":36,"completionDate":"2024-06-21"},{"nctId":"NCT04403698","phase":"PHASE2","title":"The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2019-11-13","conditions":["Erosive Osteoarthritis"],"enrollment":30,"completionDate":"2022-03-09"},{"nctId":"NCT04177940","phase":"PHASE4","title":"Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2020-08-17","conditions":["Osteoporosis"],"enrollment":45,"completionDate":"2025-08-31"},{"nctId":"NCT04338529","phase":"","title":"Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation","status":"COMPLETED","sponsor":"251 Hellenic Air Force & VA General Hospital","startDate":"2020-04-01","conditions":["Postmenopausal Osteoporosis"],"enrollment":92,"completionDate":"2024-11-01"},{"nctId":"NCT02520362","phase":"","title":"Denosumab Safety Assessment in Multiple Observational Databases","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-05-31","conditions":["Osteoporosis"],"enrollment":517991,"completionDate":"2023-07-21"},{"nctId":"NCT06621069","phase":"","title":"The Effect of Long-term Use of Bisphosphonates on Femur Morphology","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-06-01","conditions":["Osteoporosis","Knee Osteoarthristis"],"enrollment":140,"completionDate":"2024-08-01"},{"nctId":"NCT05602493","phase":"PHASE3","title":"A Randomized Control Trial Phase (IIIa) Unicentric, Placebo Controlled, Double-Blinded Efficacy and Safety of Topical Alendronic Acid on Alveolar Bone Remodeling After Tooth Extraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xeolas Pharmaceuticals Limited","startDate":"2022-11-22","conditions":["Bone Loss, Alveolar"],"enrollment":60,"completionDate":"2024-10-20"},{"nctId":"NCT00092040","phase":"PHASE3","title":"A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-03-18","conditions":["Osteoporosis, Postmenopausal"],"enrollment":936,"completionDate":"2005-09-28"},{"nctId":"NCT00480766","phase":"PHASE3","title":"A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-07","conditions":["Osteoporosis"],"enrollment":173,"completionDate":"2003-08"},{"nctId":"NCT00092066","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-24","conditions":["Osteoporosis","Vitamin D Deficiency"],"enrollment":717,"completionDate":"2004-05-01"},{"nctId":"NCT00480662","phase":"PHASE3","title":"A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-10","conditions":["Paget's Disease of Bone"],"enrollment":60,"completionDate":"2002-10"},{"nctId":"NCT00092014","phase":"PHASE3","title":"A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-09-01","conditions":["Postmenopausal Osteoporosis"],"enrollment":1053,"completionDate":"2004-04-01"},{"nctId":"NCT00092027","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-03-19","conditions":["Postmenopausal Osteoporosis"],"enrollment":454,"completionDate":"2004-03-15"},{"nctId":"NCT00389740","phase":"PHASE3","title":"A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-04-02","conditions":["Osteoporosis, Postmenopausal"],"enrollment":400,"completionDate":"2003-01-16"},{"nctId":"NCT06264401","phase":"NA","title":"Treatment Exercises With Core Stability and Dynamic Resistance Exercise for Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-02-01","conditions":["Postmenopausal Osteoporosis"],"enrollment":60,"completionDate":"2024-06-02"},{"nctId":"NCT03542695","phase":"EARLY_PHASE1","title":"64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2021-11-03","conditions":["Breast Carcinoma","Calcification"],"enrollment":1,"completionDate":"2024-05-31"},{"nctId":"NCT01350934","phase":"PHASE4","title":"A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-06-19","conditions":["Osteoporosis, Postmenopausal"],"enrollment":219,"completionDate":"2013-01-10"},{"nctId":"NCT00692913","phase":"PHASE3","title":"A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-06","conditions":["Osteoporosis"],"enrollment":515,"completionDate":"2010-07"},{"nctId":"NCT03396315","phase":"PHASE2","title":"Bisphosphonates for Prevention of Post-Denosumab Bone Loss","status":"COMPLETED","sponsor":"Columbia University","startDate":"2018-01-29","conditions":["IOP","Osteoporosis"],"enrollment":24,"completionDate":"2023-06-09"},{"nctId":"NCT00729651","phase":"PHASE4","title":"Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-03-20","conditions":["Osteoporosis Postmenopausal"],"enrollment":343,"completionDate":"2009-04-10"},{"nctId":"NCT01437111","phase":"PHASE3","title":"Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-10-26","conditions":["Osteoporosis"],"enrollment":200,"completionDate":"2012-12-05"},{"nctId":"NCT00019695","phase":"PHASE2","title":"Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-03","conditions":["Stage IV Prostate Cancer","Bone Metastases","Adenocarcinoma of the Prostate","Recurrent Prostate Cancer"],"enrollment":0,"completionDate":"2005-03"},{"nctId":"NCT05527548","phase":"PHASE4","title":"A Single-blind RCT to Investigate the Effect of Alendronate on Knee Function Following ACLR","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2022-12-22","conditions":["ACL Reconstruction"],"enrollment":64,"completionDate":"2025-12-31"},{"nctId":"NCT02944799","phase":"PHASE2","title":"Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2015-12","conditions":["Rheumatoid Arthritis","Osteoporosis"],"enrollment":69,"completionDate":"2021-12-20"},{"nctId":"NCT04555317","phase":"NA","title":"Bone Toxicity Following Pelvic Radiotherapy","status":"UNKNOWN","sponsor":"The Christie NHS Foundation Trust","startDate":"2021-05-17","conditions":["Gynecologic Cancer","Radiotherapy Side Effect","Fracture"],"enrollment":80,"completionDate":"2025-08"},{"nctId":"NCT01460654","phase":"PHASE2","title":"Testosterone and Alendronate in Hypogonadal Men","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2011-10","conditions":["Hypogonadism","Osteopenia","Osteoporosis"],"enrollment":44,"completionDate":"2014-12"},{"nctId":"NCT00580047","phase":"NA","title":"Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2003-12-01","conditions":["Renal Insufficiency"],"enrollment":59,"completionDate":"2014-07-29"},{"nctId":"NCT03623633","phase":"PHASE4","title":"Comparative Antiresorptive Efficacy Discontinuation of Denosumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2018-11-30","conditions":["Osteoporosis, Postmenopausal","Osteoporosis"],"enrollment":51,"completionDate":"2023-08-01"},{"nctId":"NCT05366621","phase":"","title":"Post-fracture Medication and Mortality","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-11-01","conditions":["Osteoporosis","Osteoporosis Fracture","Drug Therapy","Mortality","Adherence, Medication"],"enrollment":216155,"completionDate":"2021-10-31"},{"nctId":"NCT02195895","phase":"PHASE2","title":"Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2014-04","conditions":["Spinal Cord Injury","Bone Loss","Osteoporosis"],"enrollment":17,"completionDate":"2016-08-05"},{"nctId":"NCT05771038","phase":"EARLY_PHASE1","title":"Assessment of Bone Quality After Socket Preservation Using Sodium Alendronate Gel Compared to Sticky Bone","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-04","conditions":["Bone Quality Assessment","Preserved Sockets","Sodium Alendronate","Sticky Bone"],"enrollment":32,"completionDate":"2023-07"},{"nctId":"NCT05662358","phase":"NA","title":"Denosumab vs Alendronate After Vertebroplasty","status":"UNKNOWN","sponsor":"Shenzhen People's Hospital","startDate":"2021-01-03","conditions":["Denosumab Allergy"],"enrollment":90,"completionDate":"2023-10-25"},{"nctId":"NCT05325515","phase":"PHASE4","title":"The Effect of Effervescent Alendronate on Bone Turnover","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2021-10-01","conditions":["Osteopenia or Osteoporosis"],"enrollment":64,"completionDate":"2022-12-01"},{"nctId":"NCT01875458","phase":"","title":"Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2012-04-13","conditions":["Osteoporosis, With or Without Treatment","Bisphosphonate Treatment","Atypical Femur Fracture","Bisphosphonate Related Osteonecrosis of the Jaws (BRONJ)","Healthy Volunteers"],"enrollment":314,"completionDate":"2022-10-30"},{"nctId":"NCT02440581","phase":"NA","title":"Renal Osteodystrophy: An Individual Management Approach","status":"COMPLETED","sponsor":"Hartmut Malluche, MD","startDate":"2015-07-01","conditions":["Kidney Failure, Chronic"],"enrollment":141,"completionDate":"2021-06-30"},{"nctId":"NCT05645289","phase":"PHASE4","title":"Efficacy and Safety of Minodronate in Patients With Low Back Pain","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-01-01","conditions":["Postmenopausal Osteoporosis"],"enrollment":72,"completionDate":"2024-04-01"},{"nctId":"NCT00896532","phase":"PHASE2","title":"Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-06-03","conditions":["Low Bone Mineral Density","Postmenopausal Osteoporosis"],"enrollment":419,"completionDate":"2016-02-18"},{"nctId":"NCT05397938","phase":"PHASE2","title":"Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis","status":"UNKNOWN","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2022-06-15","conditions":["Glucocorticoid Induced Osteoporosis"],"enrollment":231,"completionDate":"2023-06-01"},{"nctId":"NCT05387200","phase":"PHASE4","title":"Phase IV Clinical Trial to Evaluate Efficacy and Safety of MASI BONE S (Alendronate Sodium Trihydrate) in Postmenopausal Women With Osteoporosis","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2021-07-02","conditions":["Osteoporosis"],"enrollment":170,"completionDate":"2023-05"},{"nctId":"NCT02322099","phase":"PHASE4","title":"Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss","status":"TERMINATED","sponsor":"University College Dublin","startDate":"2016-05","conditions":["Bone Demineralization"],"enrollment":53,"completionDate":"2019-09"},{"nctId":"NCT04739592","phase":"PHASE4","title":"A Study of Alendronate Sodium Vitamin D3 Tablets on Knee Osteoarthritis","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-07-07","conditions":["Knee Osteoarthritis"],"enrollment":60,"completionDate":"2024-07"},{"nctId":"NCT05305183","phase":"PHASE3","title":"A Phase III Clinical Study of Minodronate Tablets in Postmenopausal Women With Osteoporosis","status":"UNKNOWN","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2022-05-31","conditions":["Osteoporosis"],"enrollment":330,"completionDate":"2024-05-31"},{"nctId":"NCT00806416","phase":"PHASE1","title":"A Study of the Bioequivalence of 70 mg Alendronate and 70 mg Alendronate in Combination With 2800 IU Vitamin D","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-05","conditions":["Osteoporosis"],"enrollment":244,"completionDate":"2004-01"},{"nctId":"NCT01065779","phase":"","title":"FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-03","conditions":["Osteoporosis"],"enrollment":880,"completionDate":"2010-07"},{"nctId":"NCT00803790","phase":"PHASE1","title":"A Study of the Bioequivalence of 70-mg Alendronate and 70-mg Alendronate in Combination With 5600 IU Vitamin D (MK0217A-253)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-05","conditions":["Osteoporosis"],"enrollment":318,"completionDate":"2006-07"},{"nctId":"NCT00398931","phase":"PHASE3","title":"FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1998-02","conditions":["Osteoporosis, Postmenopausal"],"enrollment":1099,"completionDate":"2003-10"},{"nctId":"NCT00398606","phase":"PHASE3","title":"A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1995-04","conditions":["Osteoporosis, Postmenopausal"],"enrollment":650,"completionDate":""},{"nctId":"NCT01077817","phase":"","title":"Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-02-26","conditions":["Esophageal Cancer","Squamous Cell Carcinoma","Adenocarcinoma"],"enrollment":684815,"completionDate":"2012-02-16"},{"nctId":"NCT00641771","phase":"PHASE1","title":"4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-05","conditions":["Osteoporosis"],"enrollment":56,"completionDate":"2005-08"},{"nctId":"NCT05162885","phase":"EARLY_PHASE1","title":"Effect of Sodium Alendronate on the Final Implant Stability.","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2021-05-01","conditions":["Anterior Labial Wall Defect"],"enrollment":24,"completionDate":"2022-10-01"},{"nctId":"NCT02304757","phase":"NA","title":"99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis","status":"COMPLETED","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2015-01","conditions":["Differentiated Thyroid Cancer","Osteoporosis"],"enrollment":142,"completionDate":"2019-12-30"},{"nctId":"NCT04169698","phase":"PHASE2,PHASE3","title":"Alendronate Versus Denosumab in Kidney Transplant Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-10-17","conditions":["Osteoporosis, Osteopenia","Renal Transplant Recipient"],"enrollment":90,"completionDate":"2021-05-01"},{"nctId":"NCT00921557","phase":"PHASE2","title":"Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-11","conditions":["HIV Infection"],"enrollment":52,"completionDate":"2017-01"},{"nctId":"NCT02132026","phase":"PHASE2","title":"Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis.","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2014-11-12","conditions":["Calcific Aortic Stenosis"],"enrollment":152,"completionDate":"2019-11-28"},{"nctId":"NCT02371252","phase":"PHASE4","title":"Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2014-04","conditions":["Osteoporosis"],"enrollment":140,"completionDate":"2016-12"},{"nctId":"NCT03197623","phase":"PHASE1","title":"Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids","status":"COMPLETED","sponsor":"Nancy E. Lane, MD","startDate":"2016-10-14","conditions":["Osteopenia","Osteoporosis","Osteonecrosis"],"enrollment":58,"completionDate":"2021-03-31"},{"nctId":"NCT04861142","phase":"","title":"Osteoporosis Treatment Protocol in Patients With Fragility Fractures: Application and Efficacy","status":"UNKNOWN","sponsor":"University General Hospital of Heraklion","startDate":"2021-04-23","conditions":["Osteoporosis"],"enrollment":350,"completionDate":"2024-10"},{"nctId":"NCT03051620","phase":"","title":"Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2017-02-01","conditions":["Osteoporosis"],"enrollment":142,"completionDate":"2019-01-31"},{"nctId":"NCT04719572","phase":"NA","title":"Intervention Study of Drugs in Patients Osteopenia and Osteoporosis","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-03","conditions":["Osteoporosis","Osteopenia, Osteoporosis"],"enrollment":180,"completionDate":"2023-01"},{"nctId":"NCT04704947","phase":"PHASE3","title":"Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis","status":"RECRUITING","sponsor":"Sherief Abd-Elsalam","startDate":"2017-10-01","conditions":["Beta Blocker Toxicity"],"enrollment":50,"completionDate":"2030-10-01"},{"nctId":"NCT01657162","phase":"PHASE3","title":"Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis","status":"COMPLETED","sponsor":"Radius Health, Inc.","startDate":"2012-11-20","conditions":["Postmenopausal Osteoporosis"],"enrollment":1139,"completionDate":"2016-10-03"},{"nctId":"NCT03435094","phase":"","title":"Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes","status":"UNKNOWN","sponsor":"Labatec Pharma SA","startDate":"2018-02-25","conditions":["Osteoporosis, Postmenopausal"],"enrollment":80,"completionDate":"2022-12-01"},{"nctId":"NCT02781805","phase":"PHASE1","title":"Pilot Study of Bisphosphonates for Breast Cancer","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2016-08-05","conditions":["Breast Neoplasms"],"enrollment":6,"completionDate":"2018-12-12"},{"nctId":"NCT01656629","phase":"NA","title":"Stem Cell Recruitment in Osteoporosis Therapy","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2012-08","conditions":["Low Bone Density"],"enrollment":55,"completionDate":"2020-08-07"},{"nctId":"NCT00919711","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-09-01","conditions":["Osteoporosis"],"enrollment":870,"completionDate":"2012-03-05"},{"nctId":"NCT00354302","phase":"PHASE3","title":"Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2006-04-24","conditions":["Breast Cancer","Osteoporosis"],"enrollment":497,"completionDate":"2012-01-06"},{"nctId":"NCT03005678","phase":"PHASE4","title":"Denosumab Versus Bisphosphonates (Alendronate) in GIOP","status":"COMPLETED","sponsor":"Tuen Mun Hospital","startDate":"2017-04-01","conditions":["Osteoporosis"],"enrollment":140,"completionDate":"2020-02-01"},{"nctId":"NCT00421343","phase":"PHASE3","title":"Secondary Prevention of Osteoporosis","status":"COMPLETED","sponsor":"Hebrew SeniorLife","startDate":"2007-02","conditions":["Osteoporosis"],"enrollment":29,"completionDate":"2008-06"},{"nctId":"NCT00518531","phase":"PHASE3","title":"Denosumab Adherence Preference Satisfaction Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-09-01","conditions":["Osteoporosis"],"enrollment":250,"completionDate":"2010-06-01"},{"nctId":"NCT04140006","phase":"PHASE1,PHASE2","title":"Efficacy of Antiresorptive and Bone Forming Material on Dental Implants","status":"UNKNOWN","sponsor":"University of Baghdad","startDate":"2019-07-01","conditions":["Partial Edentulism"],"enrollment":20,"completionDate":"2020-07-01"},{"nctId":"NCT03980847","phase":"PHASE2","title":"Evaluation, the Histomorphometric Study of Nanocrystalline Hydroxyapatite (Nano Bone) Wif Alendronate in the Preservation of the Tooth Socket","status":"COMPLETED","sponsor":"Islamic Azad University, Sanandaj","startDate":"2018-02-23","conditions":["Bone Resorption"],"enrollment":20,"completionDate":"2019-04-25"},{"nctId":"NCT01588509","phase":"PHASE1","title":"Transition From Alendronate to Romosozumab (AMG 785)","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-03-30","conditions":["Osteoporosis"],"enrollment":60,"completionDate":"2012-11-21"},{"nctId":"NCT01526278","phase":"PHASE1","title":"Pharmacokinetics of Maxmarvil® in Healthy Postmenopausal Women","status":"COMPLETED","sponsor":"Yuyu Pharma, Inc.","startDate":"2011-10","conditions":["Osteoporosis"],"enrollment":18,"completionDate":"2012-09"},{"nctId":"NCT01406613","phase":"","title":"Resolution of Effect of Bisphosphonates on Bone in Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2010-03","conditions":["Postmenopausal Osteoporosis"],"enrollment":86,"completionDate":"2015-11"},{"nctId":"NCT01512446","phase":"PHASE3","title":"Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy","status":"TERMINATED","sponsor":"Evangelisches Krankenhaus Lutherhaus gGmbH","startDate":"2012-02","conditions":["Osteoporosis"],"enrollment":436,"completionDate":"2013-03"},{"nctId":"NCT03006003","phase":"PHASE4","title":"Osteoporosis Treatment in Post-menopausal Women","status":"UNKNOWN","sponsor":"Taichung Veterans General Hospital","startDate":"2017-01-01","conditions":["Depressive Syndrome"],"enrollment":500,"completionDate":"2021-12"},{"nctId":"NCT02731040","phase":"","title":"Exome Sequencing for Atypical Femoral Fractures","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-04","conditions":["Atypical Femoral Fractures","Osteoporosis","Bisphosphonate Therapy"],"enrollment":38,"completionDate":"2018-03-29"},{"nctId":"NCT03692143","phase":"","title":"Comparation of Treatment Strategies for OVF: Teriparatide Injection and PVP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2017-01-01","conditions":["Osteoporosis, Postmenopausal","Vertebral Fracture","Quality of Life"],"enrollment":90,"completionDate":"2030-12-01"},{"nctId":"NCT00145977","phase":"NA","title":"Texture Analysis for Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2001-07","conditions":["Osteoporosis","Osteopenia"],"enrollment":36,"completionDate":"2009-12"},{"nctId":"NCT01101048","phase":"PHASE1","title":"An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-06","conditions":["Osteopenia"],"enrollment":74,"completionDate":"2012-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Solution, Tablet","formulations":[{"form":"SOLUTION","route":"ORAL","productName":"Alendronate Sodium"},{"form":"TABLET","route":"ORAL","productName":"ALENDRONATE SODIUM"},{"form":"TABLET","route":"ORAL","productName":"Alendronate"},{"form":"TABLET","route":"ORAL","productName":"Alendronate Sodium"},{"form":"TABLET","route":"ORAL","productName":"alendronate sodium"},{"form":"TABLET","route":"ORAL","productName":"FOSAMAX"},{"form":"TABLET","route":"ORAL","productName":"FOSAMAX PLUS D"},{"form":"TABLET","route":"ORAL","productName":"Fosamax"},{"form":"TABLET, COATED","route":"ORAL","productName":"Fosamax"},{"form":"TABLET, EFFERVESCENT","route":"ORAL","productName":"Binosto"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148414","MMSL":"131536","NDDF":"005056","UNII":"X1J18R4W8P","VUID":"4020932","CHEBI":"CHEBI:2567","VANDF":"4020932","INN_ID":"6462","RXNORM":"203152","UMLSCUI":"C0771311","chemblId":"CHEMBL870","ChEMBL_ID":"CHEMBL870","KEGG_DRUG":"D00939","DRUGBANK_ID":"DB00630","PDB_CHEM_ID":" 212","PUBCHEM_CID":"2088","SNOMEDCT_US":"1217581008","IUPHAR_LIGAND_ID":"3141","SECONDARY_CAS_RN":"121268-17-5","MESH_DESCRIPTOR_UI":"D019386"},"formularyStatus":[],"originalProduct":{"form":"TABLET","route":"ORAL","company":"Merck Sharp & Dohme Corp.","brandName":"FOSAMAX","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1995-","companyName":"Merck And Co Inc","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"3.1 hours","clearance":"2.6 mL/min/kg","bioavailability":"1%","fractionUnbound":"0.22%","volumeOfDistribution":"0.33 L/kg"},"publicationCount":192,"therapeuticAreas":["Bone"],"atcClassification":{"source":"DrugCentral","atcCode":"M05BA04","allCodes":["M05BA04","M05BB03","M05BB05","M05BB06"]},"biosimilarFilings":[],"originalDeveloper":"Merck And Co Inc","recentPublications":[{"date":"2026 Mar","pmid":"41840835","title":"Signal detection of drug-induced esophageal ulcer across 20 years of real-world study: Focus on 49 high-risk medicines.","journal":"The Journal of international medical research"},{"date":"2026 Feb 11","pmid":"41738726","title":"[Drug related lipid metabolism abnormalities: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS)].","journal":"Nutricion hospitalaria"},{"date":"2026 Feb 18","pmid":"41706364","title":"Single-cell mapping of cholesterol metabolism reveals FDPS as a therapeutic vulnerability in hepatocellular carcinoma.","journal":"Cellular oncology (Dordrecht, Netherlands)"},{"date":"2026 Feb 16","pmid":"41697320","title":"Potential risk signals for drug-related osteomyelitis: a comprehensive disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS) database.","journal":"Naunyn-Schmiedeberg's archives of pharmacology"},{"date":"2026 Apr","pmid":"41624534","title":"Alendronic acid modified PLGA drug delivery system loaded with 17β-Estradiol and vitamin D3 has anti-osteoporotic effect.","journal":"Materials today. Bio"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Merck And Co Inc","companyId":"merck","modality":"Small molecule","firstApprovalDate":"1995","aiSummary":"","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"7964212","territory":"US","patent_type":null,"expiry_date":"2023-03-06T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7488496","territory":"US","patent_type":null,"expiry_date":"2023-08-11T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9592195","territory":"US","patent_type":null,"expiry_date":"2031-12-05T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:04:56.407280+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}